Main Web Site : www.henderson-morley.com

On line shop web site : http://www.herpesexpert.com (Frost and Simpson)

Investor Relations email : investors@henderson-morley.com

Henderson Morley is a drug discovery company

The company has been developed specifically to carry out preliminary sourcing and screening of candidates to combat diseases caused by the herpes family of viruses and certain other DNA viruses

Latest GECR update 15th October 2006

Latest GE&CR update - 15th Oct 2006 :


The news investors have all been waiting for - regarding negotiations with a US dermatological pharmaceutical firm has finally been unveiled. The licence has been granted under an agreement to
Cutanea, a U.S. pharmaceutical company, specialising in the development of dermatology products in the US market.

The licence is for new applications of ICVT for the treatment of dermatological conditions in humans. The agreement and takes the form of an exclusive American, Mexican and Canadian wide licence to bring products to market through a programme of pre-clinical and clinical development of treatments either by Cutanea or through a sub-licence. Under the terms of the Agreement, Henderson Morley will receive up to 6.675 million dollars in development and commercialisation milestone payments up to the point at which the application receives regulatory approval, and will receive royalties on net sales thereafter.

Under its business plan, Henderson Morley has stated its belief that, following clinical development and regulatory licence approval, sales of the product in excess of $1.5 billion could be achieved over the subsequent ten year period. This would give a potential royalty to Henderson Morley in excess of $115 million over this term.

As a drug discovery company, it is imperative that Henderson continues to grant licenses to further develop its technology portfolio. This is the group's third ICVT license agreement. Encouragingly, Cutanea has a great management team with a proven track record of commercialising dermatology products.

Meanwhile, the company has announced that it has been working away on a vaccine against Koi Carp Herpes virus. The group believes it is now ready to start field trials of a
candidate vaccine, in a collaboration with the Internationally renowned Hagerman
Aquaculture Research Institute in Idaho USA. The initial immunogenicity studies should produce results within 6 months, enabling Henderson Morley scientists to optimise the vaccine formulation, with a view to securing a product licence from the veterinary authorities as soon as practicable.

Clearly activity at Henderson Morley has been significant in recent weeks. The licensing announcement is very encouraging, but with the news now out of the way, the shares have eased - a classic case of buy on the rumour, sell on the news. That said, the stock has now pulled back below the recent placing price. With so much going on at the company, further newsflow in the shorter term is far from unlikely.

*Henderson Morley is a corporate client of Bishopsgate Communications which is owned by RSH, the ultimate owner of GE&CR.

Forecasts and a formal recommendation are suspended ahead of the publication of a detailed note next month.

*Henderson Morley - Initiation of Coverage with a Speculative Buy rating at 1p

19th April 05

Henderson Morley is in the process of exploiting its new, patented technology that could revolutionise the treatment of some common diseases - and some not so common. The company is currently focusing on the Human Papilloma Virus (HPV) and adenovirus - types of virus that are responsible for non-life threatening conditions such as conjunctivitis, skin warts, genital warts and verrucae, but also more serious conditions such as cervical cancer. The platform actually stops viruses from forming within an infected cell by affecting its salt balance. This is a new way of targeting virus activity and its products will be unique in the market place.

Because salts such as potassium and sodium are essential for the function of cells, altering the balance of salts within a cell by this method could result in other beneficial applications, not just for the treatment of viruses. This is another avenue the company is keen to exploit, which could open other revenue streams.

The potential revenues generated by its treatment pipeline are enormous and the company is carefully seeking licensing partners to ensure that it can fully exploit this revenue stream. Costs are being managed effectively and its first product, for the treatment of viral conjunctivitis, is in phase II trials.

The investment risk with this company is effectively lower than in some of its biotechnology peers, as the company is exploiting proven chemical compounds with decades of extensive safety testing. The products will also be novel and target an increasingly important area of biological research - anti-viral activity.

Should the company meet its licensing and milestone payment targets, the upside to the shares is potentially enormous. On a risk weighted DCF basis we value the company at up to 12.8 million pounds - around 4 times the current market value. The shares are a speculative buy.

*This report cannot be regarded as impartial as GE&CR has been commissioned to write it by Henderson Morley which is also a client of Bishopsgate Communications, a firm owned by RSH, the ultimate owner of GE&CR
Key Data
EPIC HML
Share Price 1p
Spread 0.9-1.1p
NMS 10,000
Market Cap. 3.2 million pounds
12 Month Range 0.825-1.55p
Shares Issued 322,300,000
Market AIM
Website www.henderson-morley.com
Sector Biotech
Cash in bank 470,000 pounds
Contact Andrew Knight. executive chairman
0121 442 4600


Background
The science behind Henderson Morley's business is at the cutting edge of current biochemical understanding - but what it is trying to do is actually quite simple. That's the beauty of the platform it has developed. In a nutshell, the company has taken 2 common drugs - which have already undergone rigorous safety testing - and has found a new way of using them to treat some very common viral conditions, when an effective treatment does not already exist. The system is called ionic contra-viral therapy, or ICVT for short, and the platform is currently in phase II trials for the treatment of viral conjunctivitis, but it has proved effective for a wide variety of conditions including skin warts, verrucae and genital warts.



What is a virus?
The discovery of antibiotics by Alexander Fleming in the 1920s revolutionised public health. It was arguably one of the greatest scientific discoveries ever made. The ability to control a simple infection was revolutionary - and it is something that we now take for granted. But the problem with antibiotics is that they do not work with viruses. A virus particle is the simplest and smallest living thing known.

And it is tiny. If you placed a virus particle next to a bacterium, the virus would be dwarfed. It consists of only a string of genetic material encased in a shell, which is mainly protein. A virus is such a simple organism that it does not have the capacity to reproduce itself. This is a major difference between bacteria and viruses. Because a virus does not have the equipment to reproduce, it has to hijack the reproductive systems of another cell - and turn it into a virus factory. An infected cell will then be used to churn out million of new viruses which will, in turn, re-infect other cells and the cycle begins once more. Henderson Morley's ICVT platform interferes with the replication of the virus within the cell - preventing fully-formed virus particles from being manufactured and killing the infection stone dead.

It is very difficult to kill a virus - that's why they are so dangerous. Some of the most serious communicable diseases known to medical science are viral in origin - HIV/AIDS, Ebola and even cervical cancer. Viruses pose a considerable challenge to the body's immune system because they hide within cells. There are many broad-spectrum antibiotics, but hardly any broad-based anti-virals. To the man on the street, the main public health threat is seen as coming from methicillin-resistant Staphylococcus aureus (MRSA), but it is actually the battle with viruses which looks likely to be the main threat and focus over the next 100 years.


Intellectual property
The company has combined 2 drugs - Digoxin and Furosemide. Digoxin is currently used for the treatment of heart failure and chronic atrial fibrillation. Furosemide is one of the top 30 prescribed drugs in the world each year. It is a diuretic and is used in the treatment of heart and liver failure. Both drugs do not have a history of being used as viral treatments - Henderson Morley's patented platform is a unique application. The topical use of Furosemide has been looked at extensively and no adverse side effects have been noted. In fact, some positive effects have been reported with the drug on an anti-inflammatory front. The situation is slightly different with Digoxin, which has shown some negative effects on patients at high doses when used to treat heart disease. However, it has been shown that the localised application of the treatment on skin at controlled concentrations is very unlikely to result in an adverse reaction. All in all, the safety of these drugs when used in topical application should not give investors any need for concern.

The company was granted a European patent for its ICVT in March 2004 and a US patent in November 2004. These will run to 2020.

Why is ICVT so unique?
What is interesting about Henderson Morley's ICVT platform is that it offers a treatment that is broader than most of the current ultra-specific virus treatments. The researchers have found that a combination of Digoxin and Frusemide alters the electrochemistry of a cell and prevents DNA viruses from reproducing. The technology does not work with RNA viruses. The main difference between the two type of virus is a slight difference in the chemical composition of the genetic material. The exact mechanism that the 2 drugs employ to prevent the virus being replicated is due to the inhibition of new viral DNA synthesis. The chemicals act in concert to changed the balance of salts in the cell - potassium in particular - and this prevents a complete virus being formed. The change in concentration is localised and not-systemic, as the treatment is applied by gel, cream or by another suitable carrier. The beauty of the treatment is that this only affects the metabolism of the cell slightly and produces no damaging effects.

Conjunctivitis now trials in Phase II
The company has licensed the conjunctivitis application of its treatment to private Austrian pharma group Croma Pharmaceuticals. This is in line with the company's strategy. Henderson Morley is not a large scale pharmaceutical group and the company does not intend to manufacture the products generated by its intellectual property. The company is more an ideas factory which aims to find effective treatments and licence their use by companies with the appropriate manufacturing and distribution set up. Croma has successfully completed Phase I trials in humans and is in the process of recruiting patients for Phase II trials. Exclusive EU and South American rights have been granted to the Austrian group, with Henderson Morley receiving a percentage of gross sales in these areas, but the company did not licence Croma in the US and Japanese territories - or the rest of the world. The company aims to seek further licensing deals once Phase II trials are complete.

There has been a slight snag in recruiting candidates for this trial - but it does not look like a serious problem in the greater scheme of things. On April 21st this year the company announced that Croma had encountered some difficulty recruiting enough patients for its trial of the treatment. Basically, the incentives for people infected with the disease to take part in the trial were not significant enough for people to commit to, what was potentially 6 or 7 visits to a medical practitioner for testing during the treatment. Chairman Andrew Knight reaffirmed his commitment to Croma as a partner, although he was disappointed completion of the trial had been delayed. Croma is attempting to recruit 140 people for the trial.

Growth strategy
The company is continuing to collect data on other disease areas relevant to ICVT and is working on improving formulation. In conjunction with its Business Development consultant, Dr Daniel Kirrcherr, the company is continuing discussions with potential partners for the dermal application of ICVT. Dr Kirrcherr is experience in the field, having held the position of business development director at US healthcare giant Johnson & Johnson.

The company aims to have an active presence in the ophthalmic market in 2006, with treatment for skin and genital warts as well as verrucae in the market by 2009.

Two areas of interest that Henderson Morley has taken a particular look at so far as product diversification goes, are Molluscum contagiosum; and as an orphan status treatment for respiratory papillomatosis (RRP).

Molluscum contagiosum is a relatively common condition in children, with an incidence of 2%-8% globally. There is currently no ant-viral treatment for these embarrassing skin lesions. Although this disease is associated with children, it is growing in prominence as a sexually-transmitted disease in adults because of its skin-to-skin contact transmission mechanism.

If a disease is rare and life threatening and there is no adequate treatment then it may qualify as "orphan status." The approval process for products granted this status is faster, cheaper and less clinically rigorous. Henderson Morley is examining whether the ICVT treatment could be used as an orphan status treatment for respiratory papillomatosis. This is a rare, unpleasant disease that results in the growth of numerous wart-like lesions in the respiratory tract.



Directors & Management
Andrew Knight - Executive chairman and main investor in the company. He is a successful entrepreneur with significant small business development experience.
Dr Ian Pardoe - Chief executive and developer of one of the company's antiviral candidates. He also has more than 15 years of medical practice experience.
Chris Pate - Finance director and qualified chartered accountant.
Professor Michael Fowler - Non-executive director and professor of biotechnology at Sheffield University. Dr Fowler was also a founding director of Phytera Inc, which assembled a diverse collection of plant species in culture and has industrialised their growth and manipulation in the laboratory before the company was sold to American company Galileo Laboratories.


Balance Sheet, Cashflow & Financial Results
The latest financial results for the company are from the 6-month period to October 31st, which showed pre-tax losses of 391,331 pounds, compared with losses of 377,365 in the same period in the previous year. Cash at the bank as of October 31st 2004 was 476,600 pounds. The company says it has sufficient funding through to the first quarter of 2006, so it should not be tapping the market soon for further funding. The company also has a relatively low cash burn - especially for one that operates in this company's field of operation - which currently stands at around 65,000 pounds a month.

In the 2004 financial reporting year the company reduced its loss per share to 0.36p from 0.4p in the prior year. Pre-tax losses increased, however, to 773,903 pounds from 684,793 pounds in 2003.


Shareholders
Chairman Andrew Knight owns 22.50%
Director Dr Ian Pardoe owns 13.40%.

The directors currently have options over 15.4 million shares. There are 322 million shares in issue.

The bulk of the shares are held by private investors.

Risks
The biotechnology sector by its very nature has a certain degree of risk for investors - and it has never been for the feint hearted. The success or failure of trials can make or break a share price and there are many regulatory hoops to jump through. That said, the risks associated with this particular biotechnology group are less than with most. The company has a relatively low cash burn for a biotech company - because there is no-large scale research spend needed. The company is working on the formulations and finding deals with partners, but the most significant part of the R&D has already been accomplished. The company is now pushing the products through the appropriate testing and regulatory systems and working on partnership and licensing deals. The company's management is also prudent on their fixed costs. This cost control is welcome in any business and bodes well for its expansion. There is a major advantage in the fact the two compounds used as the basis of the ICVT platform are widely know, widely used and have both been approved as treatments for decades. This eases any regulatory risk associated with the shares, but obviously does not eliminate it completely.


Potential market size
In order to make an assessment of the potential future revenues from this company, it is essential to look at the size of the market in which the company operates. There are, obviously, a number of assumptions made in the valuation, but these assumptions are deliberately conservative. So, with the platform development further along the approval line for a treatment for viral conjunctivitis, let's quantify the market for Henderson Morley's platform in this area.

It is very likely that you have suffered from an eye infection at some point in your life. It is a relatively common condition that is annoying and unpleasant - but is hardly a "serious" matter. Any sufferer would welcome a cheap and easy solution to the problem - but exactly how widespread is the disease?

It is very difficult to quantify exactly how many cases there are each year because the condition is not a notifiable disease, but a trawl through available data from a diverse range of sources can give a good indication of the number of potential cases of adenovirus-induced eye infections. A study published in the British Medical Journal found that 2%-5% of all medical consultations concerned the eye - with 44% of these down to infective conjunctivitis. A separate study in the same respected journal found that about half of these infective cases are caused by viruses. According to the Royal Society of General Practitioners and Royal College of Ophthalmologists, around 35% of all eye problems presented in general practice are infective conjunctivitis, with 13-14 cases per 1000 population each year.

This data allows for a rough calculation of the number of cases of viral conjunctivitis each year in the UK. If, conservatively, we use the lower figure from the study published in the British Medical Journal, then 2% of GP consultations concern the eye. Between 35%-40% of these infections are a result of infective conjunctivitis. Half of these infections are caused by a virus, so we can assume that around 20% of GP consultations that involve the eye are down to viral conjunctivitis. The average number of GP consultation in the UK between 1972 and 2001 was 4 per person. With the UK population standing at around 60 million people, the rough calculation below gives an idea of its incidence:

Percentage of consultations that involve the eye x incidence of viral conjunctivitis in eye infections x UK population
= 2% x 20% x 60,000,000
= 0.02 x 0.2 x 60,000,000
= 0.004 x 60,000,000
= 240,000 case per year in the UK

This is a conservative estimate. The incidence can also be calculated less conservatively as follows:

Percentage of conjunctivitis incidents that are viral x conjunctivitis rate per 1000 population x UK population/1000
= 50% x 13%-14% per 1000 x 60,000
= 6.25 x 60,000
= 375,000 cases per year in the UK.

Taking an average of the 2 figures indicated that UK viral conjunctivitis cases per year in the UK alone amount to just over 300,000 - and that's in the UK alone. There will be more cases if there is an epidemic of the infection and the global marketplace for such a treatment is truly massive.

Disease incidence assumptions and market penetration

Henderson Morley's scientists have worked out the incidence of each disease they are targeting based on available scientific data. The figures can be regarded as erring on the cautious side. For example, in calculating the incidence of genital warts, the company has only taken into account new incidences of the infection going forward, rather that taking into account the pool of several million existing cases. The table below gives an indication of the incidence of each disease that is being targeted by the ICVT platform.

Our discounted cash flow model gives the company a Net Present Value of 12.8 million pounds - significantly higher than the current 3.22 million market value.

Conclusion
Henderson Morley has a number of advantages over other biotechnology companies. The compounds used in its platform are widely known, studied and used. This should allow for ease of approval once the trial process is complete. The company's potential market is also massive, with treatments currently in the marketplace not showing the efficacy of the Henderson Morley treatment. Should the company meet its targets for licensing agreements over the coming years then the valuation above should prove conservative. There are the normal risks associated with buying shares in the biotech space, but the risks are easily identifiable - with few of them relating to the actual technology itself. The experienced management and tight cost control, bodes well for the future and, with the company currently capitalised at 3.22 million pounds at 1p, the shares are a definite speculative buy.

PpP: Thanks for posting these details. As a sufferer from conjunctivitus as well as an investor, I have tried to digest it all.
Perhaps I'm missing something here, and I'm not in any case up to speed in the medical world, but it seems to me that amid a great deal of bio-medico babble they are simply offering a mix of 2 well known drugs, digoxin and furosemide in a cream for treatment of skin problems. If so, I'm a little surprised that they have secured patents for it and would be very surprised if they were able to defend them, for some cynic is bound to pop up and say it's no different from rubbing the wound with crocus leaves. But stranger things happen in the investment world, and in any case I don't care whether it's a quack cure or a witches brew, if the punters go for it so will I. And they certainly went for it in a big way on Thursday. So I'm watching very carefully.
But my overview of the market is that the AIM stocks are mostly being by-passed by investors and so are drifting downhill. It means I'll probably be sitting on my cash for some time, maybe till St Ledger day.
sd.

Latest Update from GECR 7th Sept 2005

Henderson Morley, remains in discussions with potential partners over out-licensing its ICVT anti-viral platform. These licenses will bring milestone payments and ultimately, royalties. The company will keep the market posted on developments.

Henderson Morley has a number of advantages over other biotechnology companies. The compounds used in its platform are widely known, studied and used. This should allow for ease of approval once the trial process is complete. The company's potential market is also massive, with treatments currently in the marketplace not showing the efficacy of the Henderson Morley treatment.

Should the company meet its targets for licensing agreements over the coming years then this company is significantly undervalued. There are the normal risks associated with buying shares in the biotech space, but the risks are easily identifiable - with few of them relating to the actual technology itself. Newsflow on licensing agreement is the catalyst that is awaited and we understand that the company is in discussions with a number of parties. The shares have failed to perform since we initiated coverage but the fundamentals are unchanged and we continue to rate the shares as a "speculative buy."

Latest Update from GECR 1st Oct 2005

Henderson Morley is continuing its key discussions with potential partners over the out-licensing its ICVT anti-viral platform. These licenses will bring milestone payments and ultimately, royalties. As with any biotechnology these discussions and negotiations take time. This company's product has a huge potential market and the efficacy of the treatment against the standard viral infections it was developed for is not in doubt. The company just has to strike the right deal at the right price. The company released its annual report this month, which is available ton the company's website

Henderson Morley has a number of advantages over other biotechnology companies. The compounds used in its platform are widely known, studied and used. This should allow for ease of approval once the trial process is complete. The company's potential market is also massive, with treatments currently in the marketplace not showing the efficacy of the Henderson Morley treatment. Should the company meet its targets for licensing agreements over the coming years then this company is significantly undervalued. There are the normal risks associated with buying shares in the biotech space, but the risks are easily identifiable - with few of them relating to the actual technology itself. Newsflow on licensing agreement are the catalysts that are awaited and the company is pursuing every opportunity vigorously.

We continue to value Henderson's portfolio on a heavily risk-weighted basis at 12.8 million pounds, more than six times the current market capitalisation. On that basis our stance remains speculative buy.

Hello, there is quite of lot of buying going on today, must be news coming, something has been leaked IMO !

This level of buying does not happen on HML, so something is happening then.

looks like another of your sad tales here PpP.With a 30% spread you are asking too much for investors to punt

coeliac1 if they are all as sad as BSP today, I do not care.

The strange thing is more buys piling into HML today, I can find no reference to any tips having come up (the last time it got any large buys was the 19th May when GECR started coverage, see post 1)

Will keep looking as have a massive paper profit from BSP today so in a good mood !

Henderson Morley PLC
28 October 2005

FOR IMMEDIATE RELEASE 28 OCTOBER 2005

HENDERSON MORLEY PLC
(AIM)

Business: Drug Discovery Company

Issue of Equity
&
Patent Update

Henderson Morley plc ('the Company') announces that the Board has, today, issued and allotted, conditional upon Admission, a total of 50 million new Ordinary shares through a Placing to an investor at a price of 0.5p per share, raising 250,000 for the Company. The total number of shares in issue is now
383,928,632.

The purpose of this Placing is to provide the Company with working capital to
continue to invest in its research and development and intellectual property.

Application will be made for the new shares to be admitted to AIM and trading in the new shares is expected to commence as soon as practicable.

The Company continues to invest in patents for the further development of its
platform technology, ICVT, and has recently received notification that the
Company has been granted a second EU patent for the ICVT platform.

Several new patent applications have been filed, including patents addressing
specific product formulations, improved and enhanced potency of ICVT and for the use of ICVT in completely different (ie non viral) disease areas addressing
significant unmet medical need.

--ENDS--

Copies of this announcement will be available free of charge to the public at
the Company's registered office at Metropolitan House, 2 Salisbury Road,
Moseley, Birmingham, B13 8JS and at the offices of Brewin Dolphin Securities
Ltd, 34 Lisbon Street, Leeds LS1 4LX for 14 days.
Enquiries:

HENDERSON MORLEY PLC Tel: 0121 442 4600
Andrew Knight, Chairman

BREWIN DOLPHIN SECURITIES LTD Tel: 0113 241 0126
Neil Baldwin

BISHOPSGATE COMMUNICATIONS LTD Tel: 020 7430 1600
Maxine Barnes Mobile: 07860 489571
Dominic Barretto

Notes to Editors

Ionic Contra Viral Therapy
Developed in-house by Henderson Morley, ICVT is an innovative compound for
treating virus infections. It exploits the little known finding, that many of
the biological processes involved with virus DNA synthesis are sensitive to
local potassium ion concentrations.

ICVT uses a proprietary combination of two established drugs currently used in
cardiovascular medicine that have no prior use as anti-virals. The component
drugs used in ICVT cause depletion of intracellular potassium and inhibit the
replication of DNA viruses, while normal host cell metabolism and function is
only minimally affected. By combining two compounds that act on ion transport in different ways, the antiviral effect is enhanced. This combination therefore
offers the prospect of preventing viral replication with little or no adverse
effects.

The anti-viral effects of the two drugs in ICVT are synergistic. The effects of
ICVT on host cell metabolism have been measured in a variety of cell lines and
the rate of cell metabolism is unaffected by prolonged incubation with ICVT.
Pilot human studies have not demonstrated any local or systemic toxicity when
used at anti-virally effective doses.

Additionally, the component drugs used in ICVT have a long history of being
widely co-prescribed in the treatment of cardiovascular disease. As such, ICVT
offers potential in the treatment of a range of viral infections for which
current therapy is inadequate, such as adenovirus.

Further information on Henderson Morley plc can be accessed through the
Company's website at www.henderson-morley.com

This now clears up working cap for an extended period of time and should allow them to get something in place in terms of revenue generation.

HML playing up today, up 28%.

Another false dawn or is some good news finally just around the corner ?

It was a 3.5 million buy at way over the offer that made HML rise today, someone is confident of things to come.

More buys through and moving up again, you have to think something is happening now in the background.

Aim listed drug discovery firm Henderson Morley's recent rude market health continued, up .1p to .9p on heavy trading, after suggestions it was close to securing a licensing deal with a pharma company for one of it's anti-viral drugs.

Todays Daily Express. Market Report. David Shand. City and Business. p70.

Taken from there website;

As a drug discovery company, Henderson Morley does not have the infrastructure to take projects through the clinical trial process without a commercial partner.
Once certain in-house milestones have been achieved (typically in-vitro testing in the Company's own laboratories) partners will be sought to take a commercial licence for the technology.
This will enable Henderson Morley to continue to develop future opportunities whilst using the infrastructure and potential distribution of commercial partners.

Licensing opportunities are available for the following applications of ICVT:

Ocular infections

Dermal Infections

Veterinarian applications

Vaccines

In summary we now have the Express tip

Aim listed drug discovery firm Henderson Morley's recent rude market health continued, up .1p to .9p on heavy trading, after suggestions it was close to securing a licensing deal with a pharma company for one of it's anti-viral drugs.

13th Nov 05 Daily Express. Market Report. David Shand. City and Business. p70.


From their website;

As a drug discovery company, Henderson Morley does not have the infrastructure to take projects through the clinical trial process without a commercial partner.
Once certain in-house milestones have been achieved (typically in-vitro testing in the Company's own laboratories) partners will be sought to take a commercial licence for the technology.
This will enable Henderson Morley to continue to develop future opportunities whilst using the infrastructure and potential distribution of commercial partners.

Licensing opportunities are available for the following applications of ICVT:

Ocular infections

Dermal Infections

Veterinarian applications

Vaccines


And from the recent 28 Oct RNS;

The Company continues to invest in patents for the further development of its platform technology, ICVT, [b]and has recently received notification that the Company has been granted a second EU patent for the ICVT platform.

Several new patent applications have been filed, including patents addressing specific product formulations, improved and enhanced potency of ICVT and for the use of ICVT in completely different (ie non viral) disease areas addressing
significant unmet medical need.

I hope that the rumoured deal is for this significant unmet medical need area, but there is plenty of wood on the fire now, just waiting for the flames to come through the smoke.

Latest update from GECR 11th Dec 05;

Henderson Morley is continuing its key discussions with potential partners over the out-licensing its ICVT anti-viral platform. The company undertook a further fundraising on October 28th, raising 250,000 pounds at 0.5p a share to provide working capital for this purpose. This should be sufficient for some time as the company has a low cash burn of around 40,000 pounds per month. Once licensing deals are struck, these will bring milestone payments and ultimately, royalties. As with any biotechnology these discussions and negotiations take time - but the product is good and it works. The antiviral treatments have great scope for becoming over-the-counter medicines and the company just has to strike the right deal at the right price. We continue to believe that the potential of the Henderson Morley portfolio is not discounted in its share price and that the stock will be re-rated significantly when a licensing deal is announced.

Latest Update from GECR 8th Jan 2006

Henderson Morley is continuing its key discussions with potential partners over the out-licensing its ICVT anti-viral platform and undertook a fundraising in October, raising 250,000 pounds at 0.5p a share to provide working capital for this
purpose. This should be sufficient for some time as the company has a low cash burn of around 40,000 pounds per month. Once licensing deals are struck, these will bring milestone payments and ultimately, royalties.
As with any biotechnology operation these discussions and negotiations take time - but HM's antiviral treatments have great scope for becoming over-the-counter medicines and the company just has to strike the right deal at the right price.
Henderson Morley is in the process of exploiting its new, patented technology that could revolutionise the treatment of some common diseases - and some not so common.
The company is currently focusing on the Human Papilloma Virus (HPV) - a type of virus that is responsible for non-life threatening conditions such as conjunctivitis, skin warts, genital warts and verrucae, but also more serious conditions such as cervical cancer. The platform actually stops viruses from forming within an infected cell be affecting its salt balance. This is a new way of
targeting virus activity and its products will be unique in the market place. The potential revenues generated by its treatment pipeline are enormous and the company is carefully seeking licensing partners to ensure that it could fully exploit this revenue stream.
Management is confident that the right deal can be struck at the right price and are continuing to work towards this goal. The stance remains "speculative buy."

.

Interims out today, there is some juicy news though, this new use sounds good.

Business Review

Research continues in the anti-viral and vaccine pipeline. The technology known
as PREPS and L-particles, which was originally developed by the UK Government's
Medical Research Council Virology unit in Glasgow, is owned by the Company.
Following independent research in the USA, new and potentially valuable
applications of this technology have been discovered in the multi-billion dollar organ transplant rejection market. A new patent has been filed for the new use of PREPS and L-particles as immunomodulators, with potential application as a treatment for diseases of an overactive immune system such as Rheumatoid Arthritis, acute and chronic organ rejection and connective tissue disorders. As a result, the Company has retained a US based biotechnology licensing consultant with a view to exploiting this potential application.

The Company now has 25 granted patents in respect of its ICVT technology
platform with a significant number of other patents filed and under examination
by the patent authorities.

Any ideas on the volume and rise today PP ?

Volume and price has been rising, which could mean some news is coming ! However, with HML never hold your breath while waiting for news !

But, you never know, something is due, some kind of deal.

Latest Update from UK-analyst email GECR 13th Mar 2006

Biotechnology group Henderson Morley is continuing its key discussions with potential partners over the out-licensing its ICVT anti-viral platform following its undertook a 250,00-pound fundraising in October. The company expects to update the market with progress in this area soon. Once licensing deals are struck, these will bring milestone payments and ultimately, royalties.

As with any biotechnology company these discussions and negotiations take time. Henderson Morley is in the process of exploiting its new, patented technology that could revolutionise the treatment of some common diseases - and some not so common.
The company is currently focusing on the Human Papilloma Virus (HPV) - a type of virus that is responsible for non-life threatening conditions such as conjunctivitis, skin warts, genital warts and verrucae, but also more serious conditions such as cervical cancer.

The platform actually stops viruses from forming within an infected cell be affecting its salt balance. This is a new way of targeting virus activity and its products will be unique in the market place. The potential revenues generated by its treatment pipeline are enormous and the company is carefully seeking licensing partners to ensure that it could fully exploit this revenue stream. Management is confident that the right deal can be struck at the right price and are continuing to work towards this goal.

If such a deal will be struck the stock could be re-rated dramatically.

A small tick up on the bid side, 1 v 1 on L2.

DAILY EXPRESS 16th March 2006
* Henderson Morley expected to announce an agreed multi-million pound deal with a major pharmaceuticals group

http://www.citywire.co.uk/News/NewsArticle.aspx?VersionID=80837&MenuKey=News.Home&NewsPage=3

For long suffering HML holders, the days of happy times and faith rewarded may be coming soon. Fingers crossed !!

Shooting star :) !

Rumour has it the multi million deal is with Sanofi-Aventis

http://www.sanofi-synthelabo.us/

pp got any sp preditions?

Not at the moment Ted, need to see the size of the deal !

That's some bloody tree shake!

It was Ted, a very big one !

RNS Number:9028Z
Henderson Morley PLC
16 March 2006



FOR IMMEDIATE RELEASE 16 March 2006

HENDERSON MORLEY PLC
(AIM)

STATEMENT ON SHARE PRICE MOVEMENT

The Board of Henderson Morley plc ("Henderson Morley" or "the Company"), notes
the movement in the Company's share price this morning, and press comment today
that the Company has "agreed a multi-million pound deal with a major
pharmaceuticals group".

The Company is able to confirm that it is in an advanced stage of contractual
negotiations with a potential partner to licence certain applications of its
Ionic Contra Viral Therapy ("ICVT") technology, however no agreement has as yet
been formally agreed. The Company is able to confirm that, if an agreement is
signed, it is likely to involve the Company receiving a series of milestone,
development and commercialisation payments during the period of product
development and, ultimately, royalty payments based on sales of the products
derived from using the ICVT technology.

The Company will make a further announcement as and when appropriate.


--ENDS--

From post 23, the 13th March update from GECR, I will now happily wait for the re-rating to happen, once we get details on the deal.

Sanofi-aventis, leading European pharmaceutical group in the service of health worldwide

3rd largest pharmaceutical group in the world
Leading pharmaceutical group in France and Europe
Present in 100 countries
Nearly 100,000 employees
Pro forma net sales: 27.3 billion euros in 2005

Research the world over
17,700 research staff working on all research and development processes
Over 25 research and development centers on 3 continents
focused on performance and innovation

3rd largest R&D budget in the pharmaceutical industry: over 4 billion euros in 2005

A rich, innovative and balanced R&D portfolio: 129 products under development, 55 of which are in advanced stages of clinical investigation (phases II and III)
in seven major therapeutic areas
Cardiovascular disease
Thrombosis
Disorders of the central nervous system
Oncology
Metabolic diseases
Internal medicine
Vaccines

Read 3rd Largest, Read R&D budget, Read Vaccines = HML deal ??

From uk-analyst.com


"Having languished in the depths of sub-penny share status for longer than it would care to mention, Henderson Morley* finally broke back through the 1p barrier as a potential licensing deal loomed. The shares rose 0.44p to 1.24p. The company responded to speculation published in the Daily Express, which confirmed that it was at an advanced stage of contractual talks with a potential partner to licence certain applications of its Ionic Contra Viral Therapy technology. No agreement has yet been formally reached, however, if a deal was concluded, it would likely result in a number of significant milestone, development and commercialisation payments."

Up from the off with L2 at 2 v 1 now.

What a cracker, broken the 2p level now :)

For the next one with some good news (well I hope so) its BIT, news in within the next 2 weeks, in fact could be 2 pieces of news :) Keep a watch on it for the news, if it comes.

its overshot fair value, time to exit

oh NO.
Why sell before confirmation of a deal?
Sitting tight and thanks PP once again like you already 1 x bagger and
looking for more next week, just depends when the news comes.
Cheers Guinness calling....lol
Ted

Always the way, some will sell Friday then hope they can get back in cheaper on Monday morning, does not always work. As a deal is nearly in the bag, I am holding on and happy to wait for the news when its ready to be released.

RNS Number:0244A
Henderson Morley PLC
20 March 2006



FOR IMMEDIATE RELEASE 20 MARCH 2006

HENDERSON MORLEY PLC
(AIM)

HENDERSON MORLEY SIGNS CONTRACT FOR ICVT


The Board of Henderson Morley plc ("Henderson Morley" or "the Company"), the AIM
listed Drug Discovery Company, announces that it has today signed a term sheet
with an un-named dermatological pharmaceutical company based in the United
States of America for a potential licensing deal between the two companies.

The term sheet, which contains certain binding clauses, including a lock-out
period, gives both parties 90 days to complete a licence which will be granted
by Henderson Morley for the topical patch formulation of its Ionic Contra Viral
Therapy ("ICVT") technology P1723. It is expected that the technology will be
used to produce products ("Licensed Products") for the treatment of all
non-genital warts, including plantar warts or verrucae, and seborrhoeic
keratoses in humans, a wart-like skin condition which is common in the elderly.

The term sheet also states that the licence territory ("Territory") will cover
the United States of America, Canada and Mexico and that the licensee will fund
and use all reasonable efforts to bring the Licensed Products to market through
a programme which includes the preclinical and clinical development of the
treatment including research and development, manufacture, laboratory and
clinical testing, and marketing of the Licensed Products.

Upon signing a licence, Henderson Morley will be entitled to receive a series of
substantial milestone, development and commercialisation payments during the
programme referred to above. Details of these payments will be given at that
time.

Commenting on the announcement, Andrew Knight, chairman of Henderson Morley
said: "The granting of this licence will be a major step forward for the
Company. Once the licence has been signed, we will be in a position to give
shareholders details of the milestone and other payments which the Company will
receive, demonstrating the importance of this agreement. Furthermore, we believe
it will set the parameters from which to secure further licences for other
applications of the technology.


--ENDS--

Henderson Morley PLC
20 March 2006

FOR IMMEDIATE RELEASE 20 March 2006

HENDERSON MORLEY PLC
(AIM)
Business: Drug Discovery Company

INSTITUTIONAL HOLDING

The Company received notification on 20 March 2006 that, following the purchase of a further 2 million shares on 20 March 2006, institutional investor Billam AG is now interested in 14,461,111 ordinary shares, representing 3.8% of the issued share capital of the Company.


--ENDS--

Is it too late to join the party?? it has certainly shot up.

On the up side:

Given the 90 day lock-out, both parties are obviously keen to secure a deal. The RNS talks of "substantial milestone, development and commercialisation payments during the programme" and "The granting of this licence will be a major step forward for the Company". How much the deal is worth will ultimately determine if this is a good buying oppertunity or not.

On the downside:

Looking at the chart before the press speculation, if the deal falls through then so will the share price, probably back to where it began (way below a penny).

In my opinion, this is still only a speculative buy, and it really depends on your attitude to risk (can you afford to loose the money). Given my experience with the CHP share price, I expect this will fall if there is no news in the next week or two.

Usual disclaimer: Always do your own reasearch, and don't rely on postings here or other sites as a guide to investment.

Strawbs

Thanks S-there has been a bit of pull back today but it looks promising so will go on my watch list.

hi All
The Daily Express today reported HML signed deal worth 75million Sterling.
Although i have yet to view a copy, I have it on good authority that the article is there. hence the mad flurry of buying post 1400hrs. Is there any truth in
75m deal ???? dyor.
good luck

From a post on ADVFN;

UK-Analyste report for Tuesday:
Biotech high flyer Henderson Morley* found favour with the market yet again, adding a further 0.1p to 2.4p. This followed a research report from Growth Company & Equity Research, which forecast that the recently-announced deal with a US firm for its anti-viral applications, could have a contract value of between 28-37 million pounds, with milestone payments in the order of 3-4 million pounds. Royalty payments of between 22-31 million pounds were also said to be a possibility. GE&CR said that this inaugural licensing deal was expected to act as a framework for any future licensing deals. Even at 2.4p, Henderson is valued at just 9 million pounds, a fraction of the potential cashflow that this one deal could generate.

DYOR

Latest GECR update :

Biotechnology group Henderson Morley has signed its first major deal for its anti-viral applications with a un-named US pharmaceutical group. This deal could, on its own, be worth a multiple of Henderson's market value and we believe that further, similar, deals could be concluded over the medium term.

We believe that the total contract value for this particular deal for Henderson Morley could be in the range of 28-37 million pounds, with milestone payments extrapolated from our original forecasts estimated at around 3-4 million pounds. Royalty payments could be in the range of 22-31 million pounds.

This inaugural licensing deal is expected to act as a framework for any future licensing deals for the company's proprietary drug delivery systems. We believe that discussions on other deals for other products are still underway.

The group has a relatively simple product which it is bringing to market. The company has taken 2 common drugs - which have already undergone rigorous safety testing - and has found a new way of using them to treat some very common viral conditions, for which there is currently no effective treatment. The system is called ionic contra-viral therapy, or ICVT for short, and the platform has proved effective for a wide variety of conditions including skin warts, verrucae and genital warts. Henderson Morley has been developing the formulations of its anti-viral treatments and has taken part in typically-protracted talks that are all part of bringing a medical treatment to market. The deal announced this week covers the US, Canada and Mexico

The term sheet gives both parties 90 days to complete a licence which will be granted by Henderson Morley for the topical patch formulation of its ionic contra viral therapy technology P1723. It is expected that the technology will be used to produce products for the treatment of all non-genital warts, including plantar warts or verrucae, and seborrhoeic keratoses in humans, a wart-like skin condition which is common in the elderly.

Upon signing the licence, Henderson Morley will be entitled to receive a series of substantial milestone, development and commercialisation payments during the programme, with the details being released when the contract is finalised in the next 90 days or sooner. The table shows our original forecasts for royalty and licence payments. These forecasts are for global royalty payments and included a 10% risk weighting. Stripping out these effects and we believe that a thumbnail estimate of the milestone payments is around 3-4 million pounds, with royalty payments at around 22-31 million pounds. The full-terms of the deal are expected to be announced within 90 days.

The licensing news has prompted a significant re-rating of the company's shares, which now stand at 2.3p - well ahead of our initial buy recommendation at 1p. The licensing deal in the lucrative North American market is good news and should the company strike such deals in other territories then we believe the shares remain significantly undervalued. The shares remain a speculative buy.

along side this company,even medisys is also rising today,all looks good.what levels will hml close today,must be a hard guess the way things are going.

decided yesterday to buy a few anyway the future looks good!! glad I did after today's rise only sorry I didn't have much cash to spare but doing my research it looks as though it is a good share to keep adding on any pull back as when the partner and the size of the payments are confirmed it's likely to continue on up. IMO.

Sounds like good timing. The price looks a little too hot for me now, especially without some other fundamentals to support it. I have a nasty feeling it's reaching the top of the roller coaster, and the next phase will be a sharp correction. Hope I'm wrong. Good luck with your investment.

Strawbs

Still a ride to be enjoyed :) at the moment.

Not a fan of roller coasters myself. I also gave up on see-saws too. Everytime I jumped on the rising end it went the other way. :-) Good luck to everyone holding.

Strawbs.

notice Billam has picked up a large stake-I think I'll stay in for the ride. some large buys going through today and we should hear more within the 90 days.

PP

I would appreciate your views on this. Where do you see this going next week, and also in the medium term? I bought at 4.14p and topped up this morning at 6.05p. I'm regretting the second purchase, got caught up in the euphoria but I'm new to this and trying to learn as much as possible.

dale4j, this is the most difficult part, as a big rise needs momentum and sentiment, if the momentum fails then the price will fall, as it will with sentiment. I cannot guess up more or down or stay the same, just keep a watch. For me its long term, so I am not worried over the next few weeks movements, I will keep holding for what happens in months time and later this year. :)

PP, good to hear you believe in the long term prospects of this company. I think I will do the same as you, although if the SP reaches 10p next week, I'll probably sell 50% of my shares. You must be tempted to take some profit now, considering the price you bought these at.

dale4j I have already had a top slice, and now carry the rest for the long term ;)

Latest GECR update 15th April 2006 :

It has been an exciting period for biotechnology group Henderson Morley and patient investors have been rewarded handsomely. We have been reiterating the fact that biotech deals take time to source and finalise - but when they do, the share price response can be stellar for some months. This is what has happed with Henderson Morley. Henderson Morley shares actually hit 6.75p on March 24th, 575% significantly above the price (1p) when we initiated coverage of the stock with a "speculative buy" recommendation in May last year. The shares soared after the group signed its first major deal for its anti-viral applications with a major US pharmaceutical group. This deal could, on its own, be worth a multiple of Henderson's market value and we believe that further, similar, deals could be concluded over the medium term.

We believe that the total contract value for this particular deal for Henderson Morley could be in the range of 28-37 million pounds, with milestone payments extrapolated from our original forecasts estimated at around 4 million pounds. Royalty payments could be in the range of 22-31 million pounds. This inaugural licensing deal is expected to act as a framework for any future licensing deals for the company's proprietary drug delivery systems. We believe that discussions on other deals for other products are underway.

The group has a relatively simple product which it is bringing to market. The company has taken 2 common drugs - which have already undergone rigorous safety testing - and has found a new way of using them to treat some very common viral conditions, for which there is currently no effective treatment. The system is called ionic contra-viral therapy, or ICVT for short, and the platform has proved effective for a wide variety of conditions including skin warts, verrucae and genital warts. Henderson Morley has been developing the formulations of its anti-viral treatments and has taken part in typically-protracted talks that are all part of bringing a medical treatment to market. The deal announced this week covers the US, Canada and Mexico

The term sheet gives both parties 90 days to complete a licence which will be granted by Henderson Morley for the topical patch formulation of its ionic contra viral therapy technology P1723. It is expected that the technology will be used to produce products for the treatment of all non-genital warts, including plantar warts or verrucae, and seborrhoeic keratoses in humans, a wart-like skin condition which is common in the elderly.

Upon signing the licence, Henderson Morley will be entitled to receive a series of substantial milestone, development and commercialisation payments during the programme, with the details being released when the contract is finalised in the next 90 days or sooner. The table shows our original forecasts for royalty and licence payments. These forecasts are for global royalty payments and included a 10% risk weighting. Stripping out these effects and we believe that a thumbnail estimate of the royalty payments is around 4 million pounds, with royalty payments at around 22-31 million pounds. The full-terms of the deal are expected to be announced within 90 days of the initial announcement, which was on March 20th, possibly sooner. We have not update our forecast table below until the exact terms of the deal are confirmed.

The licensing news has prompted a significant re-rating of the company's shares, which now stand at 4.375p - well ahead of our initial buy recommendation at 1p. The licensing deal in the lucrative North American market is good news and should the company strike such deals in other territories then we believe the shares remain significantly undervalued. The shares remain a speculative buy.

cheers Papal-I've got fingers crossed for this one as a star for 2006! the research says it all.

LONDON (AFX) - Henderson Morley PLC said negotiations for the licensing
agreement for its Ionic Contra Viral Therapy (ICVT) are progressing well.
It added the pharmaceutical company with which it is negotiating has asked
to extend the scope of the proposed licence to include other applications and
discussions continue.
The company said it still expects to announce the signing of the final
contract and disclose its key terms within the original 90 day period.
In the same trading update, Henderson said it has placed 18 mln new shares
with investors at 2.5 pence per share, raising 450,000 stg.
The money raised will be used to fund working capital to continue to invest
in its patent portfolio and the ongoing development of ICVT.
newsdesk@afxnews.com

seems that people dont like the news as there are a lot more sells than buys..the mind boggles

very short sighted investors around aren't there!! I'm still happily holding mine.

From uk-analyst.com

Aim wonder stock Henderson Morley* was back in play after the company confirmed that contract negotiations were progressing well. The junior biotech group, which among its products currently in development is a potential treatment for genital herpes, said that the pharmaceutical company in question had notified Henderson that it wished to extend the scope for the proposed licence. The original 90-day window for signing the final contract and disclosing key terms was said to be very much achievable. Meanwhile a placing of 450,000 pounds worth of stock at 2.5p provides the company with further working capital to invest in its patent portfolio. The shares closed 1.225p higher at 4.4p

not sure whether to get back in ...... profited last time, but was perhaps trying to be too clever by wating until end May before venturing back ..... Real prob with HML sp, is determing its fair value if this (when) licencing deal comes off.

Latest GECR update 8th May 06

It continues to be an exciting period for biotechnology group Henderson Morley and patient investors have been rewarded handsomely. Last month, the company's shares soared as the group unveiled a deal with an un-named pharmaceuticals group for its anti-viral applications. This deal could, on its own, be worth a multiple of Henderson's market value and we believe that further, similar, deals could be concluded over the medium term.

Last month we said that we believed that the total contract value for this particular deal for Henderson Morley could be in the range of 28-37 million pounds, with milestone payments extrapolated from our original forecasts estimated at around 4 million pounds. Royalty payments could be in the range of 22-31 million pounds. However, the deal could be worth even more than this as the company has revealed that the pharmaceutical group in question had now indicated that it wished to extend the scope of the proposed licence to include other applications. Despite the further discussions, Henderson Morley still expects to be able to announce the signing of the final contract and disclose its key terms within the original 90-day period, which means we should have the full terms of the deal ahead of the next monthly update.

At the same time the company has unveiled details of a placing. The group placed 18 million new shares at 2.5p a share, raising 450,000 pounds. The total number of shares in issue is now 401,928,632. these funds will be used to provide the company with working capital to continue to invest in its patent portfolio and the ongoing development of ICVT ahead of the first milestone payments.

This inaugural licensing deal is expected to act as a framework for any future licensing deals for the company's proprietary drug delivery systems. We believe that discussions on other deals for other products are still underway. The group has a relatively simple product which it is bringing to market. The company has taken 2 common drugs - which have already undergone rigorous safety testing - and has found a new way of using them to treat some very common viral conditions, for which there is currently no effective treatment. The system is called ionic contra-viral therapy, or ICVT for short, and the platform has proved effective for a wide variety of conditions including skin warts, verrucae and genital warts. Henderson Morley has been developing the formulations of its anti-viral treatments and has taken part in typically-protracted talks that are all part of bringing a medical treatment to market. The deal announced this week covers the US, Canada and Mexico

Upon signing the licence, Henderson Morley will be entitled to receive a series of substantial milestone, development and commercialisation payments during the programme, with the details being released when the contract is finalised in the next 90 days or sooner. The table shows our original forecasts for royalty and licence payments. These forecasts are for global royalty payments and included a 10% risk weighting. Stripping out these effects and we believe that a thumbnail estimate of the royalty payments is around 4 million pounds, with royalty payments at around 22-31 million pounds. The full-terms of the deal are expected to be announced within 90 days of the initial announcement, which was on March 20th, possibly sooner. We have not update our forecast table below until the exact terms of the deal are confirmed.

The licensing news has prompted a significant re-rating of the company's shares, which now stand at 4.55p - well ahead of our initial buy recommendation at 1p. The licensing deal in the lucrative North American market is good news and should the company strike such deals in other territories then we believe the shares remain significantly undervalued. The shares remain a speculative buy.

Will the deal come off though. They have had talks before about deals which have come to nothing. Attheend of 2001 their SP tanked for nearly a year after one deal failed.

Haystack.....yeah appreciate HML have had problems in the past but this time it's the real thing. The ICVT has been throuhg it's tests and the deal was going to be announced very soon apart from the pharma wanting to extend the applications,
All positive and looking forward to a big RNS

Haystack, would like to make a prediciton then based on events of 2001 in a companies history ? Those events in 2001 were not even comparable to the proposed deal we have now.

I am glad you can be a little more sensible on here, as opposed to your endless new users names on AFN all spouting the same rubbish :) People used to listen to you before you went crazy with your barrage of user names and silly posts on there, may I suggest a return to the old Haystack ? :)

Companies like HML have failed deals all the time. There is no indication of the size of the deal anyway. It is funny how they followed the 'possible' deal with a fund raising as they wereal most out of cash. It must have made the cash raising easier.

The initial money would just be for product development and may not make them any money. Any further money (as yet unknown) would be some way in the future.

The SP would probably fall now on any announcement. Buy on rumour SELL on confirmation.

Here is a post from another BB



Some realism here!


Lightman1 - 8 Apr'06 - 11:53 - 8509 of 8509


cassius clay

It doesn't work like that. The big pharma will pay upfront milestone payments so long as they believe there is a chance of commercialisation. The profit to the company for which they have agreed a license will be virtuallly non-existent. The upfront money is to cover the entire cost of developing the product. So if HML were to recieve an upfront payment of 30 million it does not mean they'll be showing a profit of 29.5 million after the cost of developing the drug at 500K has been extracted. The size of the milestone payment is not a reflection of how wonderful the big pharma thinks the product is but the cost of developing the product. So technically HML can recieve an upfront payment of 30 million and still be showing a small loss.

The drug market is the most lucrative market after the oil industry, but like the oil its a complete bastard to bring your product on tap.

a couple of months ago, the lemmings rushed in headlong pushing the price to silly levels for no good reason .... they then all fell over the cliff ..... since then, the potential licencing deal that HML is working o in USA seems to be coming steadily to fruition, or so their last RNS indicated.

In the bloodbath of the last couple of days, the sp has stayed very solid indeed, so this may prove a useful and profitable haven for some funds ...... a similar comment could be made re ULT

Can anyone tell me when the 90 days are up and when the contract to the American Companies comes top fuition. I have lost track of the timing.I am holding on like mad for some real profit here.

And what if, as in previous discussions that HML have had, the contract is not signed?

rdo I think it is around June 12th that it will be announced. Haystack if the deal is not signed then so be it because it is high risk high reward. I'm willing to take the chance but if it fails to come off then that's the way it is !!

Monday

In a sea of red, it's good to see HML clicking up a small +0.275 albeit that the spread looks ott

and up again .... perhaps the guys really are going to pull of the licencing deal after all ..... what that means for the sp I have no idea, though a couple of months back, when sp was hyped up to 6+ peeps were talking 8/10/12p ...... Does anyone have any sensible and half-way logical assesment?

Lots of buys going through, is there some news coming?

News due around 18th and 31st July, first with (one hopes) conclusion of licencing agreement in USA and second should yield a progress report on similar talks (not due to be concluded yet) with European company

July 11th uk-analyst.com update :

Henderson Morley is delivering. Its investors are now on tenterhooks awaiting details of the company's deal to license its ICVT technology. We expect news on this front in the next few weeks, after which we will be able to fully update our forecasts. The group is currentlyin negotiations with a US group on licensing the treatment for the North American market. These talks have been protracted and both groups have now agreed to an extension. The extra 30 days means that the 2 groups now aim to strike a deal before 18 July.

The company has also said that it has been in negotiations with a European dermatological company - and those discussions had resulted in both groups signing a letter of intent. This is a precursor to the grant of a license agreement for a new application of ICVT for the topical treatment of genital and labial herpes and certain other dysplasias. It will take the form of a worldwide licence to bring the products to market through a programme of preclinical and clinical development. Both parties intend to be legally bound by the terms of a licence agreement which is expected to be concluded by 31 July.

Very few things happen quickly in biosciences and patient investors have been rewarded handsomely. The shares have soared since our initial recommendation at 1p, but we still believe that these two deals could be worth a multiple of Henderson's current market value. Indeed, the shares have performed so well since we initiated coverage of the stock, the company won a gong at the techMARK Mediscience Awards ceremony held at the Grosvenor House Hotel in London. The company won the Best Performing AIM Life Science Share award on 8 June.

We have not incorporated these 2 potential deals into our forecasts, as we await the fine details, which will hopefully emerge in the next few weeks. However, we have estimated that the total contract value for the US deal could be in the range of 28-37 million pounds, with milestone payments extrapolated from our original forecasts estimated at around 4 million pounds. Royalty payments could be in the range of 22-31 million pounds. However, the deal could be worth even more than this, as the company revealed that the pharmaceutical group in question indicated that it wished to extend the scope of the proposed licence to include other applications.

The table shows our original forecasts for royalty and licence payments. These forecasts are for global royalty payments and included a 10% risk weighting. Stripping out these effects, we believe that a thumbnail estimate of the royalty payments is around 4 million pounds, with royalty payments at around 22-31 million pounds.

The licensing announcements are good news and, should the company both capitalise on the current situation and strike further deals, we believe the shares remain significantly undervalued. The shares remain a speculative buy

Today

"due to uncertainty surrounding ongoing negotiations"

Is the deal actually going to come off? Real revenues look to be years away.

"The licence will be a worldwide licence to bring the products to market through a programme of preclinical and clinical development of the treatment."

They still have to do the trials yet.

Among the casualties, Henderson Morley was down 0.50 at 3.75 due to uncertainty surrounding ongoing negotiations with an un-named dermatological pharmaceutical company based in the US. Both parties have agreed to a further 30-day extension to Aug 17 in order to continue the negotiations, Henderson said today.

Confess that I am fast losing patience ..... don't like deals that take this long to finalise

I know that deals sometime take an age to finalise but if they delay the European deal then I might bail!

It is beginning to look very suspicious.

3.5P by the end of the week as the drift continues!!

The Year end results were slightly bizzare - turnover for the year - 2,991 (down from 5,735 in previous year). Loss 796,764

Heading down now.

Nice head of steam building up here-last chance to board the rocket?? I'm holding fingers crossed for good news any time now IMO.

"Head of steam?" "rocket"

It has been falling for more than a month and a half.

I suppose you would expect that though from a

'steam driven rocket'

LOL Haystack ! This one's on fire--how's that!! as long as it's up.

oops-fire the after burners profit takers moving in!

I am unconvinced that the up-tick is warranted by fundamentals ...... I belive HML have a history of failed deals and I find it very concerning that the US deal has now been delayed twice ..... How important the European deal is I have no idea, but I see news on that is due on Monday ...... Will that arrival (or new delay?) be as exciting as the anticipation? ..... Feeling too cynical to comment.

Look again cynics

Mondays news will be GREAT

Harvey.

Bet you thought or even said that on/about July 18th too ...... but hope you are right.

Well Harvey, you got the announcement, and market obviously considered it all a big YAWN and price even seems to have dropped 0.5p at the last knockings.

Anticlimax! And it is going to be up to 19 months plus before the procuct is ready and then longer before any revenue.

LOL

"As part of the agreement Amistad must conduct and complete certain pre-clinical and pre-development milestones including formulation, at its own cost, within a period of 18 months from the date 45 days after July 27."

The Euro pharma deal underlines where the price is, the trading range, the upside would only come from here when the US deal arrives, if it does.

The weakness of the deal announced so far might suggest a fall from here as the US deal should be similar. The revenues look to be a long way off (probably a couple of years or so).

Different deals Haystack, the Euro one was always a partnership deal, not like the US one.

I am not biased either, as only holding a small free ride of HML shares left, but the Euro one was just a sideshow, the big one remains the US deal, if they can pull that off then the shares are worth more than they are now.


From UK-analyst.com

Henderson Morley** shares edged 0.5p lower to 3p after it announced details of a license agreement for a new application of its of Ionic Contra Viral Therapy (ICVT) for the topical treatment of genital and labial herpes and certain other dysplasias. The license has been granted to French group Amistad Pharma , a company focused on women's health care. It is an exclusive worldwide licence to bring products to market through a programme of pre-clinical and clinical development. Amistad will pay Henderson Morley 40% of all net receipts received in respect of sub-licences and it will receive a royalty equal to 10% of Amistad's sales. The market is still keenly awaiting details of a US licensing agreement, which is expected to be concluded in August

What is similar is that there probably will still be testing and product development after any deal is struck, thus delaying any revenue. This is what the original announcement said in March. It sounds like it would take a long time: -

preclinical and clinical development of the treatment including research and development, manufacture, laboratory and clinical testing,

"The term sheet also states that the licence territory ('Territory') will cover
the United States of America, Canada and Mexico and that the licensee will fund
and use all reasonable efforts to bring the Licensed Products to market through
a programme which includes the preclinical and clinical development of the
treatment including research and development, manufacture, laboratory and
clinical testing, and marketing of the Licensed Products."

You are making a giant mistake Haystacks....this will come good later this month when the US deal is announced.
H.

if rather than when ..... this deal has now been delayed twice, and it is a truism that deals that take a long time rarely come out well

The revenues from the US deal are likely to be a couple of years away. In that case the price may well fall on a deal announcement. The current price reflects the US deal already. The price should drop on confirmation.

Yawn

Is it my imagination, but was not the US deal meant to be finalised on 18th August having already been delayed at least once?

yep one week to go, hmmmmmmmmmmmmmmmmmmmmm................

good rise today, someone's expecting something, will they get it?

Just made a call and bought on the (very) brave assumption that good news travels much faster than bad (old stock market adage!) ..... this morning's RNS re US talks progressing well is a couple of days in advance of the Friday "deadline" ..... judgement is now whether or not one waits for the final announcement before taking any (hope!) profit.

deal has been signed

Where is the RNS?

I've held this for a long time and recently we've see a step improvement - this is the glimmer of Light at the end of the tunnel.. but no-one knows how far that spot is - it could be a vast vista, or we could see rivals and poor deals wrecking a stellar performance.
FWIW that is why the sp is jerking about - and until the Co delivers orders and profits it will remain so. ( A good Deal would help).
Thre is nothing "certain" just yet IMHO.
However, it's a better bet "now" that ever before and I don't think Management has over-egged the business - so there is a reasonable chance they will deliver, but there is still risk.....do you feel lucky?

cynic I am surprised at your interest, this is dragging out but the yanks are tough negotiators, they must be interested, but to what degree. thought about going back in yesterday but may have missed the opportunity now, so will sit it out

Hello
Anyone in these looks like very good news
Bought a few myself today

Henderson Morley PLC
20 September 2006


FOR IMMEDIATE RELEASE 20 SEPTEMBER 2006

HENDERSON MORLEY PLC
(AIM)

Business: Drug Discovery Company

RE: NEGOTIATION PERIOD

Further to Henderson Morley's announcement on 31 August 2006, the Board is
pleased to announce that considerable progress has been made in negotiations,
and that each party now expects to be in a position to sign a licence agreement
by 27 September 2006.

The Board will provide a further update in due course.

--ENDS--


Enquiries:

HENDERSON MORLEY PLC Tel: 0121 442 4600
Andrew Knight, Chairman

BREWIN DOLPHIN SECURITIES LTD Tel: 0113 241 0126
Neil Baldwin

BISHOPSGATE COMMUNICATIONS LTD Tel: 020 7430 1600
Dominic Barretto
Nick Rome




This information is provided by RNS
The company news service from the London Stock Exchange

that's very encouraging .... by the way, RNS was released deliberately just after London market close ...... lemmings could well be leaping on board tomorrow

enjoy the ride!!!

steveo- 'enjoy the ride' the patient holders will, I have no dought.
The posters broke the record I think-- cira 500 posts in 1 day on iii,
albeit 482 of them CR+P.
Next few days trading could be fun for all--- anyone for 8p+ by next tuesday
if the deals with a big boy ?

Nice to see some news.

Not the big news, as that will be when it is signed and financials known, however it should move HML a few percent tomorrow, along with lots of tree shakes.

Great news, at least it puts down the doom mongers to a point.

I still think the Euro deal could produce a few surprises along the way, and will double up personally if I can get them cheap enough, good luck all.

dibbles,
what would you consider a fair price to get in at?

only ask as i think i missed the boat with erx
Alex

The price should drop back now over the next few days.

hmmm, missed the boat again[ long term should be good i was just looking for a quick short grab and run before i disappear off to war and cant play stocks'n'shares for a good while
Alex

Why Haystack?
IMO, sp will certainly hold until the announcement is reality on 27th ...... what happens then depends on what the deal actually is and where sp stands at the time

The deal is in the price unless it is fantastic. The short term money that came in today will be out as soon as the price flattens and it will then drop. No more news for a while and the speculatiive traders will be out. Of course the deal may not turn out to be that good and then the price will tank, which is why the short termers won't wait.

out of curiosity, do you own any shares at all in anything, or even a portfolio of short positions?

if sp had hit 6p, it's previous high when the deal with US was first mooted, i might have agreed with you ..... however, since that time, a smaller deal with a European company has been concluded, so arguably even a 6p target would not be that ambitious.

I know you disagree with that view, so have you now taken a short position yourself and if not, why not?

Good response to hayskack Mr Cynic, he let his 'doom mongering' down with
ie. 'no more news for a while'---- is next Wed a while ??? etc etc
Could we ask h/s to join the iii site amoung the 500+ crap posters 20/21st inst..
This is a clean(ish) BB site, and his coments did not profit short players albeit he
did his best--

nr

HS is fully entitled to his view, but there would seem to be a marked reticence to financially back any of his bearish statements either here or elsewhere.

And lo and behold it has fallen today. As I said above the short term money is leaving.

It looks like most holders are expecting a very good deal. If that is the case then the deal will already be in the price. If it is just a good deal then the price should fall after the deal is announced (maybe after a small short term rise)

Fair play to Haystack because the price has collapsed and is down an horrendous 1% today so give him credit LOL Anyway I'm willing to lose money if needs be but I'm expecting big things from HML!!

sorry to keep teasing you H/S, but as we have yet to establish whether or not you have any open positions of any kind in any stock, it looks as though you calld the move on HML spectacularly wrong! ...... However, the prudent may now want to consider the quantum of any upside (5.225 mid as i write), for it looks as though the lemmings are leaping on board while awaiting the news on 27th.

A bit further to fall now.

from where to where? ..... and of course it would be interesting to hear whether or not you have shorted already (and quantum of course), either HML or any other of the stocks you have attempted to dis or deramp

arguably set by trailing stopp too tight and have been shut out, but what the hell .... very nice profit and slightly above the notional target I had set at Day 1 ..... please, everyone, be careful ..... a few months ago HML rocketed and then dived again and it is certainly a truism that the anticipation proves much better than the arrival.

As I said above the deal was always in the price. The deal isn't even that good.

The money is for development and will add little to their profit.

It will be years before revenues and profit!

The MMs will beat you to death now - up a bit, down a bit, the illusion of a rally etc.

Shares rise on rumour and fall on confirmation. HML is no different.

Haystack
Not in but looks a bit over sold the deal looks OK by me, at first glance

But yes you are right Shares rise on rumour and fall on confirmation punters should read the deal.

If you have just got out have a look at ERX

HS has only proved right after the event....... in fact he called it badly wrong by calling to short when the price was still about 4p ..... in fact, ithas been above 5 for several days, reaching a high just below 6 before today's presumably momentary 6.38

For myself, i am afraid that for once i was an accurate smartarse .... see post 136

I never called to short it ever as I don't short stocks. My comments were that the deal was already in the price and it would fall on confirmation. That has been apparant for a long time. I expect it to fall quite a bit more yet to maybe 2p or lower, maybe even to 1p. Their revenue will consist only of money to commercialise their product and conduct trials for the present. That won't help their profitability much, consequently there is little point in holding these unless you don't mind a long wait.

HS .... you're full of shit ..... if you don't short any stocks, why not, given the comments you make or if you don't short, please enlighten us all as to what stocks you actually hold ...... i have asked you the same Q before but, not to my surprsie at least, you never respond ..... and before you say, "Cynic has sour grape syndrome," read back a little that I got out a few days ago with a slightly greater profit than I hoped

I rarely post on stocks that I hold. What would be the point? I posted on HML as it looked like a hyped-up stock from the start that private investors would get shafted on. This happens a lot.

Certain people spot stocks that they can ramp and do so. They get out after the suckers have pushed up the price. The price collapses and the small investors are locked in for the long term. HML was always going to turn out that way.

It became clearer when the details of a possible deal were spelt out ages ago. The initial phase would be commercialisation and testing after a licence deal. That means that revenue is a long way off. All they get for quite a time is development money. Once the licence deal is announced the price collapses as it is all jam tomorrow at that stage.

the point of posting on stocks you already hold is to impart knowledge or information or reasoning to other memebers as to why you think X looks a good investment.

that apart, for the benefit of us all, which stocks do you think are worth considering to buy (after all, you never short), for your own portfolio cannot be static? ..... or would you not post on those in case the price rose on the back of what you write?

It is more interesting and entertaining to post on bad stocks. The purpose of these BBs is just entertainment, isn't it?

in a word, NO ..... along with most others, if i want entertainment, i watch television or read a book or play golf or similar ..... so as i said, you are just a windbag (methane!) and full of shit .... suggest you migrate to ADVFN where you should find plenty of low life of similar mentality to yourself

I have been on ADV.. since 1999 and have migrated here as it is more polite and pleasant. If my posts bother you then I suggest you are more selective about what you read. Try looking at iii and you will find hoards of punterss that claim to be buying more of HML. They have been taken for suckers once and are begging to be taken for a ride again.

i assume the members of ADVFN also found you a pain ...... unfortunately your posts seem to invade certain threads that interest me

Haystack, Try posting on the AEN thread, they need a bit of help !!

Latest GE&CR update - 15th Oct 2006 :


The news investors have all been waiting for - regarding negotiations with a US dermatological pharmaceutical firm has finally been unveiled. The licence has been granted under an agreement to
Cutanea, a U.S. pharmaceutical company, specialising in the development of dermatology products in the US market.

The licence is for new applications of ICVT for the treatment of dermatological conditions in humans. The agreement and takes the form of an exclusive American, Mexican and Canadian wide licence to bring products to market through a programme of pre-clinical and clinical development of treatments either by Cutanea or through a sub-licence. Under the terms of the Agreement, Henderson Morley will receive up to 6.675 million dollars in development and commercialisation milestone payments up to the point at which the application receives regulatory approval, and will receive royalties on net sales thereafter.

Under its business plan, Henderson Morley has stated its belief that, following clinical development and regulatory licence approval, sales of the product in excess of $1.5 billion could be achieved over the subsequent ten year period. This would give a potential royalty to Henderson Morley in excess of $115 million over this term.

As a drug discovery company, it is imperative that Henderson continues to grant licenses to further develop its technology portfolio. This is the group's third ICVT license agreement. Encouragingly, Cutanea has a great management team with a proven track record of commercialising dermatology products.

Meanwhile, the company has announced that it has been working away on a vaccine against Koi Carp Herpes virus. The group believes it is now ready to start field trials of a
candidate vaccine, in a collaboration with the Internationally renowned Hagerman
Aquaculture Research Institute in Idaho USA. The initial immunogenicity studies should produce results within 6 months, enabling Henderson Morley scientists to optimise the vaccine formulation, with a view to securing a product licence from the veterinary authorities as soon as practicable.

Clearly activity at Henderson Morley has been significant in recent weeks. The licensing announcement is very encouraging, but with the news now out of the way, the shares have eased - a classic case of buy on the rumour, sell on the news. That said, the stock has now pulled back below the recent placing price. With so much going on at the company, further newsflow in the shorter term is far from unlikely.

*Henderson Morley is a corporate client of Bishopsgate Communications which is owned by RSH, the ultimate owner of GE&CR.

Forecasts and a formal recommendation are suspended ahead of the publication of a detailed note next month.

The market seems unimpressed. The price has fallen again 11% today already!

last chance to get in ERX before the milestone payment news comes out

Any one know why the rise toady?

Pump and dump over on ad fvn, get in ERX.. news soon!!! very soon

HML getting a regular mention on Trading Places: http://www.stockmarket-channel.tv/

On Mon 18

TW said he would sell all Dinsdales portfolio apart from HML

RSS of uk350.com said an interesting company that will in due course no doubt do some very interesting things
Come the spring we may have some very interesting news on the Koi Carp vaccine

That is no good reason to go out and buy them! ...... AVOID, though watch if you must

GE&CR
21st December 2006
The November Monthly View

Henderson Morley* has had a quiet month on the news front after the flurry of licensing activity over the autumn. Notably, the chairman and another director have since transferred 3.3 million shares to their SIPPs at a price of 1.64p. The two board members retain an interest in 26% of the company.

In September, Henderson announced a licensing agreement with US pharmaceuticals firm, Cutanea Life Sciences, for new applications of ICVT for the treatment of dermatalogical conditions. The agreement and takes the form of an exclusive American, Mexican and Canadian wide licence to bring products to market through a programme of pre-clinical and clinical development of treatments either by Cutanea or through a sub-licence.

Under the terms of the agreement, Henderson Morley will receive up to 6.675 million dollars in development and commercialisation milestone payments up to the point at which the application receives regulatory approval, and will receive royalties on net sales thereafter.

The group will now focus on working towards commercialisation of its patent portfolio in terms of both human and animal health, along with the development of ICVT. To this end it has secured funding of 1.2 million pounds through the issue of 60 million new shares.

Following clinical development and regulatory licence approval, sales in excess of 1.5 billion dollars of the ICVT product could be achieved over ten years. This would generate potential royalty revenues in excess of 115 million dollars for Henderson.

The shares have eased back further this month to 1.55p. With so much development going on at this drug discovery stock, further newsflow in the near term is far from unlikely. Buy

Henderson Morley up 46% today on heavy trading, anyone know why?
colombo.

No, not yet..... I picked this one up on the market scanner... bought in at 0.85p... doing ok on this one so far. I must read this thread to get to know what they actually do! I bet some good news is on the way, lets see

Cynic - On the 18th December you wrote about this company 'AVOID, though watch if you must' which sounds a bit like a retired schoolteacher who has spent a lifetime appearing knowledgeable to a bunch of 8 year olds.

What is it with you, why do you insist on posting negative stuff on a number of companies that you can't possibly have deep and detailed knowledge of?

I noticed you recently commented negatively on Party Gaming which subsequently rose by about a third, and now an almost 50% rise in the price of HM really tells us something meaningful about the quality of your investment advice.

Any other companies you hate at the moment?

Harry6
All the one's he hasn't got and some that he has.

Harry cynic i find is very balanced on his comments,each to their own with hml i guess if you bought @6p his comments would have been valid.

Sorry Capetown, utter nonsense.

On 18th December the price was 1.6 - cynic made his above quoted comment - it is now 2.2, up 45%. Backhand down the line I think.

But that isn't the point. The question I asked is why does he insist on posting negative stuff and warnings to everybody on loads of stocks that he doesn't hold!

Driver - I'll have a deal with you; the next time cynic posts a big downer on a stock, let's buy it? What do you say, anyone else in?

Harry6
I just did , bought in on the news.

HENDERSON MORLEY PLC
(AIM)

STATEMENT ON SHARE PRICE MOVEMENT

The Board of Henderson Morley plc ('Henderson Morley' or 'the Company'), notes
the movement in the Company's share price today.

The Company is able to confirm that it is in a late stage of negotiations with an
AIM-listed life sciences company. This proposed collaboration may lead to the
grant of a licence in respect of another project from Henderson Morley's product
portfolio. A further statement will be made in this respect at the appropriate
time.

The Company will be announcing its interim results for the six months to 31
October 2006 during the course of the next seven days.

--ENDS--

Harry6 i am celebrating the fact that for no reason other than a speculative one i bought 100 thou this am and i am very happy enjoy the ride

I wonder, perhaps Tepnel Life (TED )
2517

Up 103% on the day.

For god's sake Cynic, get out of that Pub/Tea-Dance/Darby & Joan Club and give us some more of your gloom. There's people on here not even millionaires yet!

*quickly scans board for more Cynic posts*

Harry6
Looking good for Monday there was only 20 minutes left of trading after the news came out, I bought in at 2.5. I want to double up or I will join Cynic and we will both be after you. LOL

Driver do you think its too late to top up at these prices?

Beware concerning buying at these levels. HML does have a habit of rising as a result of deals, but when the details come out and it is clear that money is a long way off then it falls like a stone. Look what happened in September last year.

Are you Cynic in disguise,

are you Cynic in disguise...

I agree with haystack.... be careful buying at these levels, only buy if you can sell immediately..... You might be able to make a bit more, just don't leave your computer screen....!

Whooosshhhhh

None of the deals have had up front money. The only money expected short/medium term is for product development. Real revenue is usually years away. It may be a good punt if you want to hang on to them for a few years. Short term the rise may have taken place already.

Haystack
I agree with half of what you are saying but who knows, may be the deals will keep coming?
This will definitely be marked up first thing on Monday and could go back to the 6p days.

A bit of stuff from the other side.


HML float price was 4p - without any licences or partnerships.


The stock is still undervalud on the US deal alone which could net them 100M over a 10 year period.This is achievable according to GECR.

So lets say they achieve 100M over a 10 year period from the US deal.

***10M a year for easy figures.

***Say 6M a year profit on a PE of say 15 = Mckcap of 90M from the US deal alone,dis regarding everything else.

Mckcap at the moment is 14M--3P PER SHARE.

***So at 90M the sp would be 19p per share.Sp if we had another deal similar we are looking at a Mckcap of 150M-200m OR 30P===50P per share.

Driver - interesting stuff, and thanks for that.

I bought some of these early last year and had a good profit in them until the terms of the deal were taken badly by the market back in September.

I was then looking at a loss, but I did some more work on the company and decided it was basically fine and that the fall was overdone, as most market movements seem to be these days, and bought some more to average down.

The price then fell again and I was looking at an even bigger loss, and I'd really put this one on the 2-5 year list, so I was pleasantly surprised when it all took off again today, and I'm now back in profit.

Question is, I'm off to Florence tomorrow until Wednesday - Christmas present from Mrs 6, top gift I thought - and so, do I put on a sell order for Monday morning, or do I run it and hope the price doesn't collapse again?

Incidentally, wasn't this one of ravydavygravy's tips? Anyone know what happened to him, he doesn't seem to post any more?

He was so well informed on the penny shares and he was always happy to share information.

Harry6
I don't think there is a chance of a collapse not before Wednesday anyway there is going to be speculation on how big the deal may be, is there anymore in the pipe line. If in doubt you could always sell half.

Driver thanks for your quantitative opinions, I will be waiting and seeing, hope you are right....

i have made quite a lot of money trading HML in the past, and have been fortunate enough to take my profits before sp collapsed ..... on at least 2/3 occasions!


Chart below may prove some help to you guys ....... watch out for 200 dma at about 3.20 and/or perhaps resistance at 3.80

cynic
Cheers it looks like break out then at 3.8 I think we will see that Mon morning or will we?

Todays Sat Mail 13/01/2007

Drugs minnow HML more than doubled to 305p on confirmation it is in late stage negotiations with an aim listed life science co.about a collaboration which may lead to the grant of a licence in respect of another project from its portfolio.


Could this be the company that HML are in talks with.

http://www.tepnel.com/

Why do you think this could be the company?

I think the price will shoot up in the morning, 3.8p could be the resistance level as Cynic says, but I will hange on and sell when the price starts to dip.... Keep watching thoughs screens on Monday!

It could be one of many companies heres another.

http://www.alltracel.com/


From UK-Analyst

"It was another spectacular day for the shares in Henderson Morley* (HML). The drugs discovery firm, which is a favourite among retail investors, saw its shares rise sharply on heavy volumes. In an announcement released late afternoon, the company said that it was in the late stages of negotiations with an AIM traded life sciences company. Speculation over the identity of the third party was rampant on investment bulletin boards, stirring buyers into action as almost 250 individual share purchases went through in brisk trade. The shares closed the session 1.55p higher at 3.05p as Henderson said a further announcement detailing the particulars would be unveiled within 7 days.".

emailed to over 40,000 subscribers

not sure how this hangs together .....
Harry .... i do not "have a downer" on HML .... indeed, i made quite a good profit out it in the past ..... in this instance, i have merely posted a chart and made the very accurate observation that 2/3 times in the past HML has only flattered greatly to deceive even more appallingly .... that is not to say that HML sp will not shoot ahead on Monday as hot money piles in ..... whether or not sp will warrant its hypothetical new found heights remains to be seen, but it is amazing (to some) how often the expectation far exceeds the actuality.

on the other hand, i do think PRTY is a load of rubbish and would not touch it with yours let alone mine ...... to say sp has risen 30 or is it 40% is deceptive .... more to the point is how far has it (still) fallen and what confidence can you place in its management (or future) when the founders have been selling millions and millions of shares?

by the way, why do you feel it necessary to have a greatly detaiuled knowledge of a company to make a valid judgement on whether to buy or not? ..... in some ways, that can be a hindrance (hence so many still stuck in SEO) .... to my mind, and many others, the important thing is basically momentum and whether sp is likley to keep rising at least pro tem (or even falling if shorting) ...... what the company actually does is comparatively unimportant, other than perhaps its sector ......

Dow Index is an interesting example ....... though it is undoubtedly still on a strong upward trend, it has just hit yet again 12575 (after hours), which in the past has proved a stubborn resistance ...... one could therefore make a good argument for taking a short position on Monday, albeit that sooner, probably rather than later, that resistance will be broken and the index will surge upwards again.

i'm sure you will disagree (lol!)

Harry .... you seem to have gone very quiet ...... trust you are not beginning to doubt that cynic is a total arsehole after all! ...... that said, i confess to being surprised myself at the current short-lived nature of the sp surge.

cynic
Harry's gone to Florence so his offline.

well i trust he (and you) have acted prudently

i would guess an awful lot haven't! ..... sp now well below opening and 20 million traded against 2.5 norm

actually finished with 41.5 million traded and at the bottom of it's range today!

having been told that i talked total rubbish - often true, but certainly not always - about the perils of this share, i shall just say that i for one will AVOID and think others might be well advised to follow suit!

Totally agree with Cynic in so far that the s/p of the vast majority of micro caps are determined by one variable and that is MOMENTUM fed by volume traded. ..@+ J

this is doing a repeat of last year, pump pump pump, it goes to 6p and then bang.. the news is not whats expected and poor buggers see shares at 1.5p again

if PIs have got hammered hard enough, there may be a worthwhile point to buy (and sell) before the promised announcement ...... something south of 1.8p might be a price to start looking to buy

curiouser and curiouser, said Alice, as she disappeared down the rabbit hole ....... sp down another large slug this morning (about 25%) ...... someone who e-mailed out a Buy note to 40,000 potential punters is either about to retire in style or has lost his shirt ...... and of course Cynic was talking total bollox when he advocated great caution, wasn't he!

Cynic you know i .,and many others would never think that of you!!!!

aaahhh! i am deeply touched (kiss, kiss!) ...... the cap primarily fits someone who is apparently in Florence at the mo

It is amazing that a rumour of a new deal was spresd far and wide just before the publishing of results that show widening losses.

How low would this be now if the rumour had not been spread?

!LONDON (AFX) - AIM-listed drug discovery company Henderson Morley PLC reported a widened first-half pretax loss but said it will continue to seek new opportunities to grow revenues by focusing on both human and animal health."

Haystack
This is true but so is this below; the sp will recover when there is more news. Still holding.


HENDERSON MORLEY PLC
(AIM)

STATEMENT ON SHARE PRICE MOVEMENT

The Board of Henderson Morley plc ('Henderson Morley' or 'the Company'), notes
the movement in the Company's share price today.

The Company is able to confirm that it is in a late stage of negotiations with an
AIM-listed life sciences company. This proposed collaboration may lead to the
grant of a licence in respect of another project from Henderson Morley's product
portfolio. A further statement will be made in this respect at the appropriate
time.

In fact the last time there was 'more news' about a deal the price fell as the news wasn't as good as expected. These types of deals take years to generate real profit. There is usually a product development phase first. It make well turn out to be a good company long term, but at the moment it is just sentiment driven as profits are a long, long way off.

Cynic - your posts are just a noise.

you mean like the warning bell? ...... you put your money where you like; if HML takes your fancy, then good luck to you, but be prepared to take a bath (even if, somewhat against the odds, it doesn't happen)

Sector
Biotech

Contact
Andrew Knight.
0121 442 4600


Henderson Morley has had an active month - something reflected in a n ear doubling of its share price.. The group has revealed it is in talks with a life sciences company and also unveiled interim figures.
The company confirmed on 12th January that it was in the late stage of negotiations with an AIM-listed life sciences company, the proposals of which, could lead to the grant of a licence in respect of another project from Henderson Morley's product portfolio. A further statement is expected in due course.
Meanwhile, interim numbers for the six months to 31st October were published on 16th January and showed a retained loss of 434,238 pounds, up from 352,204 pounds - a performance very much inline with expectations.
The company has now completed the Cutanea Licence Agreement for new applications of ICVT for the treatment of dermatological conditions in humans, including skin warts, verrucae and molluscum contagiosum. The Licence is an exclusive American, Mexican and Canadian wide licence to bring products to market through a programme of pre-clinical and clinical development of treatments either by Cutanea or through a sub-licence. Under the terms of the deal, Henderson Morley will receive up to 6.675 million dollars in development and commercialisation milestone payments up to the point at which the application receives regulatory approval, and will receive royalties on net sales thereafter. The Amistad License Agreement is for a new application of ICVT for the topical treatment of genital and labial herpes and certain other dysplasias.
With further details regarding the potential agreement with the life sciences company also a possibility in the short term, we expect the exciting pace of newsflow to continue. We continue to believe that the share price doers not reflect what is already known at a corporate level and will be publishing a new formal valuation shortly.
*Henderson Morley is a corporate client of Bishopsgate Communications which is owned by RSH, the ultimate owner of GE&CR.
Forecasts and a formal recommendation are suspended ahead of the publication of a detailed note next month.


http://www.bishopsgatecommunications.com/ourClients.htm

Morning
On the move, could we have news today
keith

kkeith2000
Tipped by brokers as under valued 6p IMO short term.

Driver, How do you know this?

Looks like RNS Today.

is 2.60/2.80 the correct/typical spread? ..... if so, that's a big move required just to break even.

of (much) better quality (still checking them out) are Southern Cross and Caretech

is this the announcement?

Don't think it is - but nonetheless shows what value there is in this share

All looks good to me; another ASM in the making after all the volatility has gone the sp will steadily grow over the coming months as the news comes in.

Driver I Agree ,all looks very exciting.

yet again good news comes out & as usual pump & dump. Can't understand as this company looks like a clear winner over the next few years.

fact ..... the market does not like, or perhaps does not trust this company to perform ...... if you fancy the sector, then better to look at quality like Caretech or Southern Cross

From the UPS thread.......

(Added by Master RSI on Mon 12 Feb 09:54 pm)

HML - Mid 2.325p
Reason - Chart looking ready for a BREAKOUT from a Symmetrical Triangle formed during the last month also the Indicators are at oversold and now rising, allways expecting news of their vaccine research with a GECR report on their findings

Indicators chart

Strange that @ Present you can sell 600,000 HML @ 2.29 & only buy 37,500 2.45 online anyone have any theorys as to why?

Market's short of stock, I'd say. But they don't want to put the price up to acquire it.

1.5 Mil Sells & only 200,000 Buys so far today & yet the price still holding firm. Seems to be some good support around this level now.

Does anyone know why HML has gone up by 17% this morning?

I think some news maybe expected Marcel

Keith

Henderson Morley PLC
28 February 2007
HENDERSON MORLEY PLC
(AIM:HML)

KOI CARP VACCINE UPDATE

The Board of Henderson Morley plc ('Henderson Morley' or 'the Company'), the AIM
listed drug discovery company, is pleased to provide the market and its
shareholders with an update in respect of the studies relating to the Koi Carp
vaccine following the announcement made on 3 October 2006.

These studies were designed to establish if the vaccine candidate is able to
boost the immune system of vaccinated fish and included dose ranging studies to
determine at what dose the vaccine should be administered. A successful vaccine
should enable Koi exposed to virus, to mount a successful immune response
against KHV and thus prevent disease. These studies examined antibody responses
to vaccination also known as antigenicity studies.

The antigenicity studies of the Koi herpes vaccine candidate have now been
completed. The data has been analysed and the Board is pleased to announce that
100% of the vaccine recipients tested have produced a significant immune
response.

This level of immunity is a very good indicator of a successful vaccine being
developed. Further field studies are ongoing and the Company will keep
shareholders informed of progress in due course.

---ENDS---

Predicted market reaction to a 100% success rate, anybody ?

Not really a good day today issue good news.

HML seems tobe quiet a bit of buying does anyone know why?

nope .... must be nutters with too much money

New monthly GE&CR update just out.



Henderson Morley, the AIM listed drug discovery company has issued an update on studies relating to the Koi Carp vaccine following an announcement made in October last year. The studies were designed to establish if the vaccine is able to boost the immune system of vaccinated fish. It included dose ranging studies to determine the exact dosage that could be administered. If successful, Koi fish exposed to virus should be able to mount a successful immune response against KHV and prevent disease. Analysis has revealed that the 100% of the vaccine recipients tested have produced a significant immune response.

This update follows news of an agreement with AIM-listed Stem Cell Sciences, which allows SCS to explore the use of HM's L-particles and PREPS technology in the design of unique stem cell based assays.
The recently completed Cutanea Licence Agreement for new applications of ICVT, for the treatment of dermatological conditions on human, is set to boost Henderson Morleys cashflow by up to US$6.675 million over the course of the deal. This will strengthen the companys balance sheet and finance its development further, resulting in more licence deals and the undertaking of more research programmes with partners in the industry. The companys prospects remain good and we continue to believe that the share price at just over 2p does not reflect the upside potential of the companys drug research and discovery licence agreements and on-going progress it has made over the last year.
Henderson Morley offers a diverse range of novel therapeutic drug development opportunities. Its patent protected intellectual property in relation to virus infections shows evidence of having wide application, particularly with regard to vaccines for serious diseases including cancer.
We have valued the Company on a heavily risk-weighted DCF-based valuation at 4.2p per share and, with the shares trading at 2.03p, this suggests upside potential of over 80%. Any further operational progress, both in terms of drug trials and in the granting of additional licences, will reduce our risk weightings on the product development portfolio and add to that core valuation. On that basis, our stance remains buy at 2.03p.

A conference being held Wednesday, May 16

Henderson morley are speakers.

http://www.pegsummit.com/07-PDL.asp

5:20 Henderson Morley
PREPS and L-Particles- A Novel Herpes Simplex Based Virus Like Particle For Delivery of a Wide Range of Therapeutic Proteins
Dr Ian Pardoe, MB ChB, Chief Executive and Medical Director, Henderson Morley plc.
It is a little known fact, that as part of the natural infectious cycle, herpes simplex viruses produce virus like particles in culture. These particles contain all of the surface and tegument proteins of the parent virus, but completely lack the nucleocapsid. These so called L-particles facilitate the natural infection of HSV, so are able to enter cells as if they were viruses. Because of the total lack of DNA, they are unable to replicate. The intellectual property regarding production of L-particles, and a further refinement; PREPS is owned by Henderson Morley and they are now being developed as therapeutic agents. Non native proteins that have been engineered into the parent virus, can be delivered functionally intact to cells. It is possible to engineer the virus to express several antigens simultaneously, so a multivalent cancer vaccine is therefore being developed. L-particles also enhance naked DNA transfection, hence its use as an adjuvant for DNA vaccines is being explored. This talk will briefly highlight the technology and its potential applications.

Some buying going on, up about 5% now don't know the reason yet

A conference being held Wednesday, May 16

May have some thing to do with it.

Roomers by the look of it, reading the other side.

I'm impatient so I've sold mine for other picks but I heard the take over talk as well around 8p--but it's a very long time coming!

Good volume today some rather big buys, it would be nice if we had some news to back the rise up or could it be another false dawn
The pattern over the weeks and months is now predictable up and down , with so many products in the pipeline it may just be a matter of time and patience

This share has been a disaster for years is there any Management intention of making it profitable, or is it a means to keep them emplopyed?
You would think that having patented a scheme they's strive to prove its worth; conduct trials on patients etc. and there has been enough time for this since about 2000, when they first listed (on Ofex, I suspect, but can't be certain).
Since coming to AIM there has been no real progress...as far as I recall....so just what are we waiting for? - and on past performance just how long will it be "in coming?" I suspect this is another never-never investment.....the World will be cured of cancer by the time anyone wakes up to this treatment.....that is if it is a treatment...or is it just a "delivery" like Tetrapac waiting in some parallel World for milk to become popular?
I have held this and you know, I'm getting rather sick of it...

KKeith2000 keeps us (here) up to date...but it's just words on the page....I don't see any commercial result....and Koi Carp are pretty ugly, couldn't they have chosen herring, the little sweeties?

hangon some of the things you say are correct but with the small caps it can sometimes work like this, a little buying lifts the s/p we all hope for news it doesn't come the personal investors get board give them back to the mm/s and the s/p drifts down
I do think we will have some good news sometime but when i don't know, some of the products the company have could be worth millions so in the meantime i will wait till i get board

Looks to be on the move, no news yet but over the past few weeks some large buying, after the risers and falls just wondering if this time we could just rise up to the final results which i think out next month and some good news

Henderson Morley PLC
20 June 2007

20 JUNE 2007

HENDERSON MORLEY PLC
(AIM:HML)

SCIENTIFIC PROGRAMME UPDATE

The Board of Henderson Morley plc ('Henderson Morley' or 'the Company'), the AIM
listed drug discovery company, is pleased to provide the market and their
shareholders with an update detailing the current status of the Company's
activities and its scientific pipeline.

HIGHLIGHTS

Discussions with a pharmaceutical partner regarding Koi Herpes vaccine at
an advanced stage;

Internationally renowned consultant retained to assist the development of
PREPS and L-particles;

It is envisaged that a final injectable formulation of ICVT will be ready
for Pre-IND discussions with the FDA by December 2007;

A specialist animal health Contract Research Organisation contracted to
undertake field studies to examine the use of ICVT topical drops in the
treatment of Feline Herpes Virus (FHV) conjunctivitis;

The first phase of the Henderson Morley's laboratory expansion is now
complete - resulting in a newly formed Molecular Virology Lab, enhanced
virus growth capabilities

Executive Chairman Andrew Knight said: 'We are continuing to see strong interest
across the portfolio as it develops. We look forward to further updating the
market in due course.'

---ENDS---

ENQUIRIES:

HENDERSON MORLEY PLC 0121 442 4600
Andrew Knight, Chairman

BISHOPSGATE COMMUNICATIONS LTD 0207 562 3350
Maxine Barnes
Nick Rome

BREWIN DOLPHIN SECURITIES LTD 0113 241 0126
Neil Baldwin


SCIENTIFIC PROGRAMME UPDATE

Koi Herpes vaccine

The Company is pleased to announce that it is in late stage discussions with a
pharmaceutical partner in respect of a licence for the vaccine.

The initial immunogenicity studies regarding the Company's proprietary vaccine
against Koi Herpes Virus (KHV) demonstrated potent antibody responses. Further
studies using a virus neutralising assay have shown that not only were
antibodies produced by the vaccine, but these demonstrated virus neutralising
effects.

A reliable immunofluorescence assay has now also been developed, as well as
larger scale virus production and a variety of standardisation and quality
control measures.

Further announcements will be made in due course.

PREPS and L-particles

This technology, which uses non replicating virus particles that totally lack
DNA, was presented to an International Congress on Protein Therapeutics in
Boston (PEGS Summit, Boston InterContinental Hotel, 16 May 2007). This
generated considerable interest within the scientific community and therefore a
further presentation will be made in August at the 2007 Cancer Immunotherapies
Conference in Cambridge Mass., USA.

To advise on the development of this technology, the Company has retained
internationally renowned consultant Professor Lemoine. Professor Lemoine holds
his chair at Queen Mary's School of Medicine (at Barts and the London Hospital)
and is Director of both the Institute of Cancer, and the Cancer Research UK
Clinical Centre. He also leads the Centre for Molecular Oncology.

Laboratory based studies are progressing well, using state of the art virus
engineering techniques to produce viruses that express marker proteins for
immunogenicity studies - a precursor to pre-clinical and clinical studies.

Other in-house studies are also making good progress in exploring the use of
these particles as candidates for human herpes virus vaccines.

ICVT formulation

The development of an injectable formulation of ICVT in conjunction with the
University of Aston, Pharmaceutics department, is nearing completion.
Standardised assays have been developed and initial chemistry and release
studies have also been completed. It is envisaged that a final formulation will
be ready for Pre-IND discussions with the FDA by December 2007.

Feline Herpes

Previous in-vitro studies completed in-house have demonstrated that the Feline
Herpes Virus (FHV) is extremely sensitive to the effects of ICVT. Consequently,
Henderson Morley is pleased to announce that a specialist animal health Contract
Research Organisation has now been contracted to undertake field studies to
examine the use of ICVT topical drops in the treatment of FHV conjunctivitis.

The studies are expected to start within 60 days, with results of the study
anticipated within Q1 2008.

The studies will examine animals that are already infected by FHV. The animals
will be given drops to be applied by their owners or by veterinary health care
professionals. No animals will be harmed in these studies, ethics committee
approval will be gained, and the studies will be supervised by independent
veterinary advisers.

The drops to be used in this study have been shown to be safe and well tolerated
in human studies. If the cats were not enrolled into this study it is likely
that they would remain untreated. If the treatment proves successful, it is
likely therefore that the welfare of the cats treated in this study will be
significantly enhanced, with potential future benefit for the wider feline
community.

Feline herpes virus infections are very common, and represent a major cause of
morbidity in animal care institutions, the wild feline population and domestic
cats, especially at times of breeding.

A recent sero-epidemiolgical study demonstrated that in wild cat populations
feline herpes incidence was as high as 75%. Also in approximately one third of
clinically normal cats, it was possible to isolate virus from their respiratory
tract, and that over 97% of the whole study group had antibodies against FHV-1
by ELISA. This indicates that the infection is extremely common and is prone to
recurrence, even in those animals that are clinically normal.

There is currently no anti-viral treatment licensed to treat feline herpes
infection in the UK or any of the major markets, so a significant market
opportunity exists.

Laboratory Expansion

The first phase of the HML laboratory expansion has now been completed. This has
resulted in a newly formed Molecular Virology Laboratory with enhanced virus
growth capabilities. Virus handling and purification, sterilisation,
inactivation and quality control measures have also been enhanced.

Preliminary Results

The Company will be announcing its results for the year to 30 April 2007 before
30 September 2007.

---ENDS---

ENQUIRIES:

HENDERSON MORLEY PLC 0121 442 4600
Andrew Knight, Chairman

BISHOPSGATE COMMUNICATIONS LTD 0207 562 3350
Maxine Barnes
Nick Rome

BREWIN DOLPHIN SECURITIES LTD 0113 241 0126
Neil Baldwin


Notes to Editors:

Henderson Morley was founded in 1996 with the objective of developing its anti-
viral application (Ionic Contra Viral Therapy (ICVT). ICVT is the Lead Platform
and has been developed in-house and Henderson Morley wholly owns the patent IPR.

Further information on Henderson Morley plc can be accessed through the
Company's website at
www.henderson-morley.com

Its now fair to say until we get a licence for one of the products this share will generate little interest and you can understand why from the past

I do believe the RNS today is positive and for the brave in time will come good, but as always do your own research

On the move again could this be the one we have been waiting for?

Henderson Morley PLC
03 July 2007

3 July 2007


HENDERSON MORLEY PLC
(AIM:HML)

STRATEGIC REVIEW


The Board of Henderson Morley announces that, further to the announcement made
on 23 January 2007, the Company is continuing to explore strategic options in
order to maximise shareholder value. One of these options is the sale of some
or all of the business, and the Board has engaged advisers to assist with this
process. This process may or may not lead to an offer being made for the
Company. Consequently the Company is considered to be in an 'offer period' as
defined in the City Code on Takeovers and Mergers, and the dealing disclosure
requirements listed below will apply.

During this process the scientific development programme and out-licensing
strategy continues unaffected.

The Company will keep shareholders informed of progress in this respect.


---ENDS---


Contact:

Henderson Morley plc 0121 442 4600
Andrew Knight

Bishopsgate Communications Ltd 0207 562 3350
Maxine Barnes


Brewin Dolphin Securities
Neil Baldwin 0113 241 0130



In accordance with Rule 2.10 of the City Code of Takeovers and Mergers, as at
the close of business on 2 July 2007 it had 491,928,631 ordinary shares of 0.125
pence each in issue. The ISIN reference number for these securities is
GB0030711229.

Dealing Disclosure Requirements

Under the provisions of Rule 8.3 of the City Code on Takeovers and Mergers (the
'Code'), if any person is, or becomes, 'interested' (directly or indirectly) in
1% or more of any class of 'relevant securities' of the Company, all 'dealings'
in any 'relevant securities' of that company (including by means of an option in
respect of, or a derivative referenced to, any such 'relevant securities') must
be publicly disclosed by no later than 3.30 pm (London time) on the London
business day following the date of the relevant transaction. This requirement
will continue until the date on which the offer becomes, or is declared,
unconditional as to acceptances, lapses or is otherwise withdrawn or on which
the 'offer period' otherwise ends. If two or more persons act together pursuant
to an agreement or understanding, whether formal or informal, to acquire an
'interest' in 'relevant securities' of the Company, they will be deemed to be a
single person for the purpose of Rule 8.3.

Under the provisions of Rule 8.1 of the Code, all 'dealings' in 'relevant
securities' of the Company by the Company, or by any of its respective
'associates', must be disclosed by no later than 12.00 noon (London time) on the
London business day following the date of the relevant transaction.

A disclosure table, giving details of the companies in whose 'relevant
securities' 'dealings' should be disclosed, and the number of such securities in
issue, can be found on the Takeover Panel's website at

www.thetakeoverpanel.org.uk
.

This is going to fly now

Waited a long time for this

After a near 40% rise in the blink of an eye dropped back down a bit to 16% now
Reading the RNS it looks like the company is trying to force someones hand who as been stakebuilding

I've made my maiden purchase today at 2.76 pence. I think just on speculation we are set for the next wave off rises with HML. I would expect the price to get to nearer to 4 pence in the next few days before anyone shows their hand!

I would think so as well. The directors bought a few at 2.5 i think so they would want a fair price

Am hoping tomorrow some press coverage may throw some light on things

A new website but can't find anything on Koi Herpes vaccine

didn't know that goldfish went in for oral sex so much that herpes would give them concern ...... do they also get genital warts which are a closely related virus?

HML Anyone know when the next update is due, its now lower than it was before the last RNS. Anyone any thoughts?

Looking like sentiment is changing but a bit early to say if HML can stay above 2p and move forward.AGM 14th November 2007 which may have some bearing on recent volume.Only have a relatively small amount of these from a few months ago so haven't looked in any great detail.Interesting though!

Hmmmm,looking good but will it last?

why should it?

exactly but then again why not? :-)

All depends on news as always...............

Maybe the long rumoured bid is just around the corner--it's certainly perking up!!

hi all

Hi holly not much action on here am afraid, am still holding these in the hope they may deliver something but it's a long painful wait
Some news on the ICVT should be due soon according to a RNS on the 20 June 2007, but don't hold your breath -)

RNS Number:6594Y
Henderson Morley PLC
20 June 2007

"It is envisaged that a final injectable formulation of ICVT will be ready
for Pre-IND discussions with the FDA by December 2007"

kkeith, its the Koi deal that everyones waiting for then 6/8p minimum which could come anyday.
Good luck.

is not SEO are better bet?

Brief research, though my weekend will be spent working on this suggests this could very well be highly lucrative solution if the KHV cure can be brought to market. These koi cost tens of thousands pounds each, the owner of the KOI farms would pay handsome rewards.

http://www.digitallook.com/news/rns/1038498-14431/HML-Scientific_Programme_Update.html

Could any person answer this simple question, are any other companies closer to bringing a cure to market than HML?

A simple search using the word KHV shows the devastation this disease causes. What a silly comment SEO are better. Like comparing a rover with a BMW. I enjoy finding these little penny stocks, I have massive concerns about those 3p spikes tones of ramping; I really hope that is not the case.

Good stuff

Olivergas, none what so ever. See Thefruits comments over on the ADVFN BB.

holly12345 thanks if you do a check he has flipped. i never believe what I read on BB's good for finding places to dig. I currently hold FRR, fweb, SEG and just bought some OHM. I think I will move a few K into HML. These penny stocks bring out the kid in me.

Oilivergas, TF knows more about HML than they do he's no ramper either.
KHV due any day now along with a certain Mr Dunne picking up a few more millions this year watch for largish buys coming in, you could catch it before the spike which this time around will not fall days after.

holly12345 reading the fruit bats posts on ADVFN shows he is clueless, his post yesterday on lse shows he is headless. Away from the rampers though one guy on lse posted last sunday seem to hold more hope and checking other threads his posted the same seems to suggest all is not lost read comments by Trading.Pirate, btw I do not know him but his comment breaths an air of hope I like. A few other comments on III suggest ramping but again with a hint of longer term news. I hope the rampers bog off and allow the stock to slowly rise

Fingers crossed Oilivergas.

LOL have a look at ecpc they have made a mistake RNS is giving .95 on the 29th whilst the share price is only .2

Oilivergas, khv' s on its way by the sounds of todays rns.

I don't like a strategic Review hanging about (since July07!), to make up their mind what to do. . . . Looks a bit like Eyes-off-ball . . . . meanwhile the sp drifts down.
Hardly a "speculative Buy" ( Thread subject). . . . ''loss'' is more like it.
This co has always been poor on information and the sp drift tells it all. I have a small holding now, from higher - but then so does everyone.

Sheering-Plough deal looks OK, but [HML[ needed to raise further capital at 0.6pence, so the sp has a new-low to reach.
The Sheering-Plough deal is for Koi-Carp treatment over three-years....so a thin coating of Jam (3-years hence).
-Obviously good news if you're a Koi-carp with a rather nasty infection . . . . . and can wait 3-years.
.....Oh dear......
EDIT..May08 ...Looks like the Company is attempting to keep investors informed, as regards future programmes, income and other "forward-looking" possibilities. Whilst this is not yet "income" it may at least align Company Bosses with expectations.... (ends)

It looks like HML are on the way out. They are at an historic low and their short / medium term prospects look bleak.

Henderson Morley PLC

(the 'Company')


Directors' Shareholding


The Company received the following notification on July 22 confirming transactions in the Company's share capital by a director of the Company.

Mr A Knight, Chairman, has today purchased the following shares at the following prices:


Number Price


100,000 0.55p

350,000 0.60p

225,000 0.65p

As a result Mr Knight has an interest in 85,653,764 shares in the Company, representing 14.89 per cent. of the issued share capital of the Company.

RNS Number : 8494Z
Henderson Morley PLC
25 July 2008

25 July 2008

Henderson Morley PLC

(the 'Company')

Directors' Shareholding

The Company received the following notification on July 24 confirming transactions in the Company's share capital by a director of the Company.

Mr A Knight, Chairman, has today purchased the following shares at the following prices:
Number Price

500,000 0.60p

As a result Mr Knight has an interest in 86,153,764 shares in the Company, representing 14.97 per cent. of the issued share capital of the Company
--ENDS--

He is picking up shed loads on the cheap. Either he is worried at the sp fall or, more likely, he knows that he is going to make a packet when they finally move up.

yes,could be either but I take it as a positive sign until proven otherwise.

There must be some news out there or about to break......

Well it's not the Director Buy - just 3k's worth, less than he'd pay for a daughter's car. I do not consider a DIR purchase significant unless it's 50k+ and this is telling me quite the opposite.....better to have bought nothing...Oh deary.

For the MM's to raise the sp 30% must think we're MUGS. Following the Rules - AK will not know of any price-sensitive information - so this purchase tells us "There Is No News"

Now watch that sp fall.

Pity their treatment can't transform Koi into mermaids...or turn a dire stock into - - - . I hold from about 3p...ouch.

hangon,you sound very bitter!

I'm nearly at break even so very happy and looking forward to the future.

hangon,sorry I was a bit short with yer earlier but your post didn't make sense-lol

"Following the Rules -AK will not know of any price-sensitive information - so this purchase tells us "There Is No News""- I'm sure the Chairman knows what's going on within the company and this is the AIM after all! :-)

There may or may not be news next week but the SP held up pretty well after quite a rise.

It's his total interest in HML that counts:

"Mr Knight has an interest in 86,153,764 shares in the Company, representing 14.97 per cent."

Interesting couple of weeks for HML methinks! Is there news waiting to be announced,AK just topping up as he knows the company has or is close to making a major deal,AK just trying to add confidence with his buys and no news in pipeline or.................could go on-lol.

A lot of upside if there is positive news but will have to wait and see with this one.

Are we seeing the start of something here? Will have to be news driven to continue..........obv.

Nice little rise and the above post still applies.
:-)

RNS Number : 9870J
Nice little rise today,I see.


Henderson Morley PLC
11 December 2008

11 December 2008



HENDERSON MORLEY PLC

(AIM: HML)



('Henderson Morley' or 'the Company')



HYBRIDAN INITATES COVERAGE ON HENDERSON MORLEY



The Board of Henderson Morley plc, the AIM quoted biotechnology company, is pleased to announce that Hybridan, the Company's house broker, has today initiated coverage on the Company. To view the research note please visit http://www.henderson-morley.com/news.php



Hybridan has given Henderson Morley a buy recommendation and a target price of 4.72p. This is based on the significant revenue potential of the Company's technology platforms.



Highlights



Hybridan believes that the Company's value is mainly tied to the intellectual property related to its three technologies, which provide a competitive advantage due to their unique mechanism of action and their impressive efficacy and safety profile.


The Company has three business divisions: Pharmaceuticals (based on ICVT), Animal Health (based on ICVT and its proprietary technology PREPS and L-particles), and Vaccines (also based on PREPS and L-particles).

Given the impressive revenue potential and low costs of development and production of its programmes, Hybridan believes that Henderson Morley has the potential to out license its candidates and sign deals with up front-, ongoing milestone- and royalty payments.


Using a probability-adjusted Sum of the Parts (SOTP) DCF model, Hybridan estimates Henderson Morley's fair value at 4.72 pence per share, with ICVT, Animal Health and Vaccines contributing 29%, 68% and 4%, respectively.


Hybridan believes a number of indications are not included in its valuation and Henderson Morley's progression in these would provide an obvious upside.



---ENDS---

http://moneyam.uk-wire.com/cgi-bin/articles/200812111515079870J.html

23 December 2008


HENDERSON MORLEY PLC

(AIM: HML)

Koi Vaccine Update

The Board of Henderson Morley announces that further to the Chairman's statement which accompanied the results for the full year, the initial phase of the field studies has now been completed.

The vaccine candidates under examination were formulated to give a wide range of doses, using proprietary adjuvants (compounds that help boost and increase the duration of immune responses). The results from the study have demonstrated that the vaccine candidates were safe and well tolerated, with adverse effects no greater than unvaccinated controls.

Fish were vaccinated and examined, amongst other parameters, for immune responses to vaccination, vaccination dose, vaccination safety and assessment of the safety and immunogenicity of the new adjuvant. The studies have given a much greater understanding of immune responses and dose requirements. It is likely that from the next phase of studies, due to start in Jan 2009, a final vaccine candidate will be selected.

Commenting on the announcement, Andrew Knight, Henderson Morley Executive Chairman said: 'This is an important first stage in studying the efficacy of the KHV vaccine. We can now move forwards to the next phase of the study which we anticipate will start in early January 2009.'

http://moneyam.uk-wire.com/cgi-bin/articles/200812230700106408K.html

A little bit of movement here too!

Hmmmmmm........

14January 2009


HENDERSON MORLEY PLC
(AIM: HML)
('HendersonMorley' or 'the Company')

DOG CANCERCOLLABORATION

Henderson Morley ispleased to announce the start of a Collaborative Research Programme withaUSbased centre of excellence for companion animal cancer. The centre is the largest research unit for animalcancers intheUS, and the collaborationisto develop treatmentsfor twodifferent forms of dog cancer.

For the first time, the studies will exploretheuseof PREPS and L-particlesas a treatment for cancer. The studywill involve dogsthatalreadyhavecancer, andtheir existing treatment has either failed or is likely to prove ineffective.

PREPS and L-particles have beenengineered to express proteins that are only found in tumours, or are over produced by certaincancers.Inaffected animals, these proteins are not recognised by the immune system as beingforeign, and therefore thetumours areable to grow.PREPS and L-particles present these engineered proteins to the immune systemsothat animmune response is expected to be generated against them,mobilising the animals'immune system against the tumours.

The market fordog cancertreatmentsis significant and growing, as dogs are living longer, and pet ownership is increasing. There are 74 million dogs owned in theUS, with 4 million new dog cancer diagnoses being made every year.We believe that the numbers in the EU are similar.Thefirsttwo cancers under investigation are two of the most common forms of dog cancerwith a large potential market.

The data generated in these studies will also be extremely useful in support of the on-going licensing efforts for the use of PREPS and L-particles as treatments for human cancer.

Ethics committee approval for the first of these two studies has been granted, and the second is expected to be approved withina fewweeks.It is expected tostart recruitingpatients in March-Aprilwith approximately 10 animals involved in each study.The time taken to gain marketing approval for companion animal cancer products is significantly shorter than the human equivalent.

The Company isalreadyindiscussionswith major animal health companies to seekdevelopmentagreementsoran out-licenceof thecompanioncancerapplications of PREPS and L-particles.

Executive ChairmanAndrew Knightsaid'This is an important potential commercial application for thePREPS and L-particles vaccine platformand we are pleased to be working with the Centre of Excellence in this respect. The companion animal market is clearly a growing opportunity forHendersonMorley.'

---ENDS--

Please take with a pinch of salt but of interest:

Henderson Morley

By Alistair Dawber
Monday, 19 January 2009

Dogs, and sometimes cats, are said to be man's best friend, which is why people spend hundreds or thousands of pounds each year on vet bills. Aim-listed Henderson Morley, the veterinarian biotech group, understand the value of this market, especially in the United States, where the group is collaborating on research with "a US-based centre of excellence for companion animal cancer".

Much like humans, dogs and cats can expect to live longer than ever today, as a result of improved diets and better understanding of their health needs. The consequence, however, is that animals are more prone to conditions associated with old age, including cancers. Of the 74 million dogs and cats in the United States, 4 million each year are diagnosed with cancer. The Henderson Morley research centre will initially concentrate on melanomas and lymphomas, which form a third of all cancers in dogs.

The group's shares are largely held by individuals, and are illiquid as a result: last week's news about the research centre caused barely a ripple. If the centre produces results, and Henderson Morley is able to tap what is a hugely lucrative market, you can be sure that the stock will fly.

http://www.independent.co.uk/news/business/sharewatch/small-talk-end-is-nigh-for-aims-nasty-little-businesses-1419359.html

Share Offer extended by abt a week - - - -does this mean punters aren't biting - er, this one isn't.

Considering ( as suggeested here), HML products sell into a Market that's resillient to prices - they seem to have a demand for cash - and this business has been a LT failure as far as LT investors are concerned - I recall it went to 7p at one time ( DYOR).

on board this morning at .46p....been watching this for a long time....suck it and see! as they say!.... GL all...

Whats up..?

from another board...

"All buys today 5M on LSE and 4M on plus. 9 more days of this and the 100M will be gone ! Then we might see an increase in the sp! Or do the buyers of the 9M today know somethink is near to completion ??"

Thanks for that sky I noticed the buying this am and bought a few.

Good Golly, this is a poor LT investment. Over the years it's seen a 90% fall - are there ever any companies worth investing in?
EDIT -(11May2010)-Grief, 0.21p and an extension to "due-dilligence" - Arrgh!

bought some more on the back of this morning's RNS..there is a big hang over of shares still to shift but don't see the sp going much lower than this. (imho)

Ah so! Directors are supplying their own money to keep this sick elephant in whacky-grass. I suppose one should be grateful they can - but let's face it, IF they ran the Co in the way the Market would expect, then this business would be profitable....and about to ramp-up to new-levels as their technology spawnned new opportunities.....the facts speak as loud as the sp..
. . . . . . . . . . This is a missed opportunity and way off missed targets. . . . . . .

The RNS hints that they expect to sell their technology...."Fire Sale" springs to mind....I know this business from about 10 years ago and it's been downhill all the way. Perhaps Directors should be paying to stay with the company - for it is evident their presence is not benefitting retail shareholders.

DYOR - all IMHO etc.

Skyhigh, I'm sorry to see the sp has halved since March2010 and yr investment probably more-so with Dealing costs, spread etc. If you've held from long-ago (like me!) then you've only averaged-down....something that is very tempting to "expunge one's losses" - but reality it's like paying more to get a ring-side seat at a match that's already into injury time with most players littering the field..
EDIT (17/8/10),RNS=Good News - Directors found 5k under the photocopier, so heads held high.....Grr!

Yep. it's desperate isn't it!..have averaged down abit sinceand have sold a bit but still holding on to some waiting for a miracle to happen (which won't)

Administration I'm afraid skyhigh and I'm sure it won't be the only one over the next 12 mnths.

I can't believe that this hasn't died yet. I have been followign HML for quite a time now and seen the constant ramping that pushed the price up. I hope that not too many people have lost their money on this.

Its long gone the bigger they are the bigger the fall.

Oh well! another one bites the dust...hardly surprising with this one,,,initial layout a couple of years ago of 700....had gone down to about 250....should've sold a long while ago!